1
|
Chapman LS, Alcacer-Pitarch B, Pauling JD, Flurey CA, Redmond AC, Richards P, Herrick AL, Merkel PA, Proudman S, Menz HB, Helliwell PS, Hannan MT, Domsic RT, Saketkoo LA, Shea B, Siddle HJ. Patients' perspectives on systemic sclerosis-related Raynaud's phenomenon in the feet: A qualitative study from the OMERACT Foot and Ankle Working Group. Semin Arthritis Rheum 2024; 65:152372. [PMID: 38325052 DOI: 10.1016/j.semarthrit.2024.152372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Revised: 12/11/2023] [Accepted: 01/03/2024] [Indexed: 02/09/2024]
Abstract
OBJECTIVE To explore, from patients' perspectives, the symptoms and impact of Raynaud's phenomenon (RP) on the feet of patients with systemic sclerosis (SSc-RP), and to identify which foot-related domains are important to patients. METHODS Forty participants (34 women) with SSc-RP took part in one of six focus groups held in the United Kingdom or United States. Participants were purposively sampled to ensure diversity in disease type, duration, and ethnicity. The topic guide included questions on RP impact, self-management, and treatment expectations. Qualitative content analysis was employed to identify key concepts in the data relating to foot-specific symptoms and their impact. Themes were organized by corresponding domains of potential importance. RESULTS Twenty-eight participants (70 %) reported experiencing RP in their feet. Five themes were identified corresponding to domains of potential importance: temperature changes, pain, cramping and stiffness, numbness, and color changes. These issues negatively affected participants' lives, impairing walking, driving, and socializing, and causing issues with footwear and hosiery. CONCLUSIONS This large qualitative study exploring the experiences of patients with SSc-RP in the feet identified several key domains of high importance to patients. SSc-RP is common in the feet, presents in several patterns, and impacts multiple aspects of patients' lives. These findings indicate where future foot-specific interventions for RP could be targeted. Findings from this study improve understanding of what domains are important to patients with SSc-RP affecting the feet and will contribute to the development of a core outcome set for foot and ankle disorders in rheumatic and musculoskeletal diseases.
Collapse
Affiliation(s)
- Lara S Chapman
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
| | | | - John D Pauling
- Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Bath, Bath, UK; University of Bath, UK
| | - Caroline A Flurey
- School of Social Sciences, College of Health, Science and Society, University of the West of England, Bristol, UK
| | - Anthony C Redmond
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, UK
| | | | - Ariane L Herrick
- Centre for Musculoskeletal Research, The University of Manchester, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | - Peter A Merkel
- Division of Rheumatology, Department of Medicine, Division of Clinical Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, USA
| | - Susanna Proudman
- Discipline of Medicine, University of Adelaide and Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia
| | - Hylton B Menz
- School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Victoria, Australia
| | - Philip S Helliwell
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
| | - Marian T Hannan
- Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Beth Israel Deaconess Medical Center, Boston, MA, USA
| | - Robyn T Domsic
- University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | | | - Beverley Shea
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Heidi J Siddle
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
| |
Collapse
|
2
|
Sattui SE, Xie F, Wan Z, Clinton C, Domsic RT, Curtis JR. Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Analysis from the American College of Rheumatology RISE Registry. Arthritis Care Res (Hoboken) 2024; 76:259-264. [PMID: 37563714 DOI: 10.1002/acr.25216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Revised: 07/05/2023] [Accepted: 08/08/2023] [Indexed: 08/12/2023]
Abstract
OBJECTIVE This study describes the demographics, comorbidities, and treatment patterns in a national cohort of patients with polymyalgia rheumatica (PMR) who received care from rheumatology providers. METHODS Patients with PMR were identified in the American College of Rheumatology Rheumatology Informatics System for Effectiveness registry from 2016 to 2022. Use of glucocorticoids and immunomodulatory antirheumatic medications used as steroid-sparing agents were examined overall and in a subgroup of patients new to rheumatology practices, the majority with presumed new-onset PMR. In these new patients, multivariate logistic regressions were performed to identify factors associated with persistent glucocorticoid and steroid-sparing agent use at 12 to 24 months. RESULTS A total of 26,102 patients with PMR were identified, of which 16,703 new patients were included in the main analysis. Patients were predominantly female (55.8%) and White (46.7%), with a mean age of 72.0 years. Hypertension (81.2%), congestive heart failure (52.4%), hyperlipidemia (41.3%), and ischemic heart disease (36.0%) were the most prevalent comorbidities. At baseline, 92.3% of patients were on glucocorticoids, and only 13.1% were on a steroid-sparing agent. At 12 to 24 months, most patients remained on glucocorticoids (63.8%). Although there was an increase in use through follow-up, antirheumatic medications were prescribed only to a minority (39.0%) of patients with PMR. CONCLUSION In this large US-based study of patients with PMR receiving rheumatology care, only a minority of patients were prescribed steroid-sparing agents during the first 24 months of follow-up; most patients remained on glucocorticoids past one year. Further identification of patients who would benefit from steroid-sparing agents and the timing of steroid-sparing agent initiation is needed.
Collapse
Affiliation(s)
| | - Fenglong Xie
- University of Alabama at Birmingham and Foundation for Advancing Science, Technology, Education and Research, Birmingham, Alabama
| | - Zihan Wan
- Duke Cancer Institute-Biostatistics Shared Resource, Duke University Medical Center, Durhame, North Carolina
| | | | | | - Jeffrey R Curtis
- University of Alabama at Birmingham and Foundation for Advancing Science, Technology, Education and Research, Birmingham, Alabama
| |
Collapse
|
3
|
Kim JS, Woods A, Gutierrez-Alamillo L, Laffoon M, Wigley FM, Hummers LK, Rosen A, Zeger S, Domsic RT, Casciola-Rosen L, Shah AA. Distinct Scleroderma Autoantibody Profiles Stratify Patients for Cancer Risk at Scleroderma Onset and During the Disease Course. Arthritis Rheumatol 2024; 76:68-77. [PMID: 37488962 PMCID: PMC10807373 DOI: 10.1002/art.42663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Revised: 06/08/2023] [Accepted: 06/11/2023] [Indexed: 07/26/2023]
Abstract
OBJECTIVES We examined whether an array of scleroderma autoantibodies associates with risk of cancer and could be useful tools for risk stratification. METHODS Scleroderma cancer cases and scleroderma controls without cancer from the Johns Hopkins Scleroderma Center and the University of Pittsburgh Scleroderma Center were studied. Sera were assayed by Lineblot and enzyme-linked immunosorbent assay (ELISA) for autoantibodies against centromere, topoisomerase 1, RNA polymerase (POLR) 3, PM/Scl, Th/To, NOR90, U3 RNP, Ku, Ro52, U1RNP, and RNPC3. Logistic regression models were constructed to examine whether distinct autoantibodies associated with overall cancer at any time and cancer-associated scleroderma (cancer occurring three years before and after scleroderma onset). The effects of having more than one autoantibody on cancer were further examined using random forest analysis. RESULTS A total of 676 cases and 687 controls were studied. After adjusting for relevant covariates, anti-POLR3 (odds ratio [OR] 1.47, 95% confidence interval [CI] 1.03-2.11) and monospecific anti-Ro52 (OR 2.19, 95% CI 1.29-3.74) were associated with an increased overall cancer risk, whereas anticentromere (OR 0.69, 95% CI 0.51-0.93) and anti-U1RNP (OR 0.63, 95% CI 0.43-0.93) were associated with lower risk. When examining risk of cancer-associated scleroderma, these immune responses remained associated with increased or decreased risk: anti-POLR3 (OR 2.28, 95% CI 1.33-3.91), monospecific anti-Ro52 (OR 2.58, 95% CI 1.05-6.30), anticentromere (OR 0.39, 95% CI 0.20-0.74), and anti-U1RNP (OR 0.32, 95% CI 0.11-0.93). Anti-Ro52 plus anti-U1RNP or anti-Th/To was associated with decreased cancer risk compared with anti-Ro52 alone. CONCLUSIONS These data suggest that five distinct scleroderma immune responses, alone or in combination, may be useful tools to stratify the risk of cancer for scleroderma patients. Further study examining cancer risk in autoantibody subgroups relative to the general population is warranted.
Collapse
Affiliation(s)
- Ji Soo Kim
- Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD USA
- Johns Hopkins Bloomberg School of Public Health, Department of Biostatistics, Baltimore, MD USA
| | - Adrianne Woods
- Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD USA
| | | | | | - Fredrick M. Wigley
- Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD USA
| | - Laura K. Hummers
- Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD USA
| | - Antony Rosen
- Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD USA
| | - Scott Zeger
- Johns Hopkins Bloomberg School of Public Health, Department of Biostatistics, Baltimore, MD USA
| | | | - Livia Casciola-Rosen
- Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD USA
| | - Ami A. Shah
- Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD USA
| |
Collapse
|
4
|
Pauling JD, Yu L, Frech TM, Herrick AL, Hummers LK, Shah AA, Denton CP, Saketkoo LA, Withey J, Khanna D, Domsic RT. Construct validity and reliability of the assessment of systemic sclerosis-associated raynaud's phenomenon (ASRAP) questionnaire. Rheumatology (Oxford) 2023:kead371. [PMID: 37481713 DOI: 10.1093/rheumatology/kead371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Accepted: 06/27/2023] [Indexed: 07/24/2023] Open
Abstract
OBJECTIVES Assessment of construct validity and reliability of a novel patient-reported outcome (PRO) instrument for assessing the severity and impact of Raynaud's phenomenon (RP) in systemic sclerosis (SSc). METHODS An international multicentre study validation study of the 27-item Assessment of Systemic sclerosis-associated RAynaud's Phenomenon (ASRAP) and 10-item short-form (ASRAP-SF) questionnaires. The relationship between ASRAP questionnaires and demographics, clinical phenotype and legacy instruments for assessing SSc-RP severity, disability and pain was assessed. Repeatability was evaluated at 1-week. Anchor-based statements of health status facilitated assessment of ASRAP thresholds of meaning. RESULTS Four hundred and twenty SSc subjects were enrolled. There was good correlation between ASRAP (and ASRAP-SF) with RP visual analogue scale (VAS) and Scleroderma Health Assessment Questionnaire RP VAS (rho range 0.648-0.727, p< 0.001). Correlation with diary-based assessment of SSc-RP attack frequency and duration was lower (rho range 0.258-0.504, p< 0.001). ASRAP questionnaires had good correlation with instruments for assessing disability, hand function, pain and global health assessment (rho range 0.427-0.575, p< 0.001). Significantly higher ASRAP scores were identified in smokers, patients with active digital ulceration (DU), previous history of DU and calcinosis (p< 0.05 for all comparisons). There was excellent repeatability at 1-week amongst patients with stable SSc-RP symptoms (intra-class coefficients of 0.891 and 0.848, p< 0.001). Patient-acceptable symptom state thresholds for ASRAP and ASRAP-SF were 45.34 and 45.77 respectively. A preliminary Minimally Important Clinical Difference threshold of 4.17 (95% CI 0.53-7.81, p= 0.029) was estimated. CONCLUSION ASRAP and ASRAP-SF questionnaires are valid and reliable novel PRO instruments for assessing the severity and impact of SSc-RP.
Collapse
Affiliation(s)
- John D Pauling
- Department of Rheumatology, North Bristol NHS Trust, Bristol, UK
- Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Royal National Hospital for Rheumatic Diseases (part of the Royal United Hospitals NHS Foundation Trust), Bath, UK
| | - Lan Yu
- Department of Medicine, University of Pittsburgh, PA, USA
| | | | - Ariane L Herrick
- The University of Manchester, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester
| | - Laura K Hummers
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Ami A Shah
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Christopher P Denton
- Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital, London, UK
| | | | - Jane Withey
- Royal National Hospital for Rheumatic Diseases (part of the Royal United Hospitals NHS Foundation Trust), Bath, UK
| | - Dinesh Khanna
- Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital, London, UK
- University of Tulane Medical Center, New Orleans, LA, USA
| | - Robyn T Domsic
- University of Michigan Scleroderma Program, Ann Arbor, MI, USA
| |
Collapse
|
5
|
Roofeh D, Brown KK, Kazerooni EA, Tashkin D, Assassi S, Martinez F, Wells AU, Raghu G, Denton CP, Chung L, Hoffmann-Vold AM, Distler O, Johannson KA, Allanore Y, Matteson EL, Kawano-Dourado L, Pauling JD, Seibold JR, Volkmann ER, Walsh SLF, Oddis CV, White ES, Barratt SL, Bernstein EJ, Domsic RT, Dellaripa PF, Conway R, Rosas I, Bhatt N, Hsu V, Ingegnoli F, Kahaleh B, Garcha P, Gupta N, Khanna S, Korsten P, Lin C, Mathai SC, Strand V, Doyle TJ, Steen V, Zoz DF, Ovalles-Bonilla J, Rodriguez-Pinto I, Shenoy PD, Lewandoski A, Belloli E, Lescoat A, Nagaraja V, Ye W, Huang S, Maher T, Khanna D. Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease. Rheumatology (Oxford) 2023; 62:1877-1886. [PMID: 36173318 PMCID: PMC10152284 DOI: 10.1093/rheumatology/keac557] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2022] [Revised: 08/05/2022] [Accepted: 09/17/2022] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVES To establish a framework by which experts define disease subsets in systemic sclerosis associated interstitial lung disease (SSc-ILD). METHODS A conceptual framework for subclinical, clinical and progressive ILD was provided to 83 experts, asking them to use the framework and classify actual SSc-ILD patients. Each patient profile was designed to be classified by at least four experts in terms of severity and risk of progression at baseline; progression was based on 1-year follow-up data. A consensus was reached if ≥75% of experts agreed. Experts provided information on which items were important in determining classification. RESULTS Forty-four experts (53%) completed the survey. Consensus was achieved on the dimensions of severity (75%, 60 of 80 profiles), risk of progression (71%, 57 of 80 profiles) and progressive ILD (60%, 24 of 40 profiles). For profiles achieving consensus, most were classified as clinical ILD (92%), low risk (54%) and stable (71%). Severity and disease progression overlapped in terms of framework items that were most influential in classifying patients (forced vital capacity, extent of lung involvement on high resolution chest CT [HRCT]); risk of progression was influenced primarily by disease duration. CONCLUSIONS Using our proposed conceptual framework, international experts were able to achieve a consensus on classifying SSc-ILD patients along the dimensions of disease severity, risk of progression and progression over time. Experts rely on similar items when classifying disease severity and progression: a combination of spirometry and gas exchange and quantitative HRCT.
Collapse
Affiliation(s)
- David Roofeh
- Department of Internal Medicine, Division of Rheumatology, Scleroderma Program, University of Michigan, Ann Arbor, MI, USA
| | - Kevin K Brown
- Department of Medicine, National Jewish Health, Denver, CO, USA
| | - Ella A Kazerooni
- Department of Internal Medicine, Division of Rheumatology, Scleroderma Program, University of Michigan, Ann Arbor, MI, USA
- Department of Radiology, Division of Cardiothoracic Radiology, University of Michigan, Ann Arbor, MI, USA
| | - Donald Tashkin
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Shervin Assassi
- Department of Internal Medicine, Division of Rheumatology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Fernando Martinez
- Department of Internal Medicine, Division of Pulmonary Critical Care Medicine, Weill Cornell School of Medicine, New York, NY, USA
| | - Athol U Wells
- Department of Internal Medicine, Division of Pulmonology, Royal Brompton Hospital and National Heart and Lung Institute, London, UK
| | - Ganesh Raghu
- Department of Internal Medicine, Division of Pulmonology, Critical Care and Sleep Medicine, University of Washington School of Medicine, Seattle, WA, USA
| | - Christopher P Denton
- Centre for Rheumatology, Division of Medicine, University College London, London, UK
| | - Lorinda Chung
- Department of Internal Medicine, Division of Immunology and Rheumatology, Stanford University, and Palo Alto VA Health Care System, Palo Alto, CA, USA
| | | | - Oliver Distler
- Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Kerri A Johannson
- Departments of Medicine and Community Health Sciences, Section of Respiratory Medicine, University of Calgary, Calgary, Canada
| | - Yannick Allanore
- Department of Rheumatology A, Cochin Hospital, APHP, Université de Paris, Paris, France
| | - Eric L Matteson
- Department of Internal Medicine, Division of Rheumatology, Mayo Clinic, Rochester, MN, USA
| | - Leticia Kawano-Dourado
- HCor Research Institute, Hospital do Coração, São Paulo, Brazil
- Pulmonary Division, Heart Institute (InCor), University of Sao Paulo Medical School, São Paulo, Brazil
- INSERM 1152, University of Paris, Paris, France
| | - John D Pauling
- Musculoskeletal Research Unit, Bristol Medical School, University of Bristol, Bristol, UK
- Department of Rheumatology, North Bristol NHS Trust, Southmead, Bristol, UK
| | | | - Elizabeth R Volkmann
- Department of Internal Medicine, Division of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Simon L F Walsh
- National Heart and Lung Institute, Imperial College London, London, UK
| | - Chester V Oddis
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Eric S White
- Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
| | - Shaney L Barratt
- Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol, UK
- Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Southmead, Bristol, UK
| | - Elana J Bernstein
- Department of Internal Medicine, Division of Rheumatology, Columbia University School of Medicine, Vagelos College of Physicians and Surgeons, New York, NY, USA
| | - Robyn T Domsic
- Department of Internal Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Paul F Dellaripa
- Department of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Richard Conway
- Department of Internal Medicine, Division of Rheumatology, Trinity College Dublin, University of Dublin, Dublin, Ireland
| | - Ivan Rosas
- Department of Internal Medicine, Division of Pulmonology, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Nitin Bhatt
- Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Vivien Hsu
- Department of Internal Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA
| | - Francesca Ingegnoli
- Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università degli Studi di Milano, Milano, Italy
| | - Bashar Kahaleh
- Department of Internal Medicine, Division of Rheumatology, University of Toledo Medical Center, Toledo, OH, USA
| | - Puneet Garcha
- Department of Internal Medicine, Division of Pulmonology, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Nishant Gupta
- Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati, Cincinnati, OH, USA
| | - Surabhi Khanna
- Department of Internal Medicine, Division of Rheumatology, University of Cincinnati, Cincinnati, OH, USA
| | - Peter Korsten
- Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany
| | - Celia Lin
- Genentech, Inc, San Francisco, CA, USA
| | - Stephen C Mathai
- Department of Internal Medicine, Division of Pulmonology, Critical Care and Sleep Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Vibeke Strand
- Department of Internal Medicine, Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA
| | - Tracy J Doyle
- Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Virginia Steen
- Department of Internal Medicine, Division of Rheumatology, Georgetown University School of Medicine, Washington, DC, USA
| | - Donald F Zoz
- Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
| | - Juan Ovalles-Bonilla
- Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Ignasi Rodriguez-Pinto
- Autoimmune Disease Unit. Deaprtment of Internal Medicine. Hospital Mutua de Terrassa, University of Barcelona, Barcelona, Spain
| | - Padmanabha D Shenoy
- Department of Rheumatology, Center for Arthritis and Rheumatism Excellence, Kochi, Kerala, India
| | - Andrew Lewandoski
- Department of Internal Medicine, Division of Rheumatology, University of Michigan-Metro Health, Grand Rapids, MI, USA
| | - Elizabeth Belloli
- Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA
| | - Alain Lescoat
- Department of Internal Medicine, Division of Rheumatology, Scleroderma Program, University of Michigan, Ann Arbor, MI, USA
- Department of Internal Medicine and Clinical Immunology, Rennes University Hospital, Rennes, France
- Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Rennes, France
| | - Vivek Nagaraja
- Department of Internal Medicine, Division of Rheumatology, Scleroderma Program, University of Michigan, Ann Arbor, MI, USA
| | - Wen Ye
- Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA
| | - Suiyuan Huang
- Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA
| | - Toby Maher
- Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Southern California, Los Angeles, CA, USA
| | - Dinesh Khanna
- Department of Internal Medicine, Division of Rheumatology, Scleroderma Program, University of Michigan, Ann Arbor, MI, USA
| |
Collapse
|
6
|
Calderon LM, Domsic RT, Shah AA, Pope JE. Preventative Care in Scleroderma: What Is the Best Approach to Bone Health and Cancer Screening? Rheum Dis Clin North Am 2023; 49:411-423. [PMID: 37028844 PMCID: PMC10845237 DOI: 10.1016/j.rdc.2023.01.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/09/2023]
Abstract
Systemic sclerosis (SSc) is a rare multisystem autoimmune disease characterized by fibrosis, vasculopathy, and autoimmunity. Lesser known complications inherent to SSc, such as malignancies and osteoporosis, can lead to decreased quality of life and increased morbidity and mortality. Patients with SSc have a greater risk of developing malignancies than the general population. In addition, they are more likely to be vitamin D deficient and are at great risk of osteoporosis-related fractures. However, these complications can be addressed through preventative measures. The purpose of this review is to provide clinicians with an approach to bone health and cancer screening in SSc.
Collapse
Affiliation(s)
- Leonardo Martin Calderon
- Department of Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada
| | - Robyn T Domsic
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Ami A Shah
- Johns Hopkins Scleroderma Center, Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F. Lord Building Center Tower, Suite 4100, Baltimore, MD 21224, USA.
| | - Janet E Pope
- Department of Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada; Division of Rheumatology, University of Western Ontario, St. Joseph's Health Care, 268 Grosvenor Street, London, Ontario N6A 4V2, Canada.
| |
Collapse
|
7
|
Calderon LM, Pope JE, Shah AA, Domsic RT. Preventative Care in Scleroderma: What Is the Best Approach to Vaccination? Rheum Dis Clin North Am 2023; 49:401-410. [PMID: 37028843 PMCID: PMC10875978 DOI: 10.1016/j.rdc.2023.01.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/09/2023]
Abstract
Systemic sclerosis (SSc) is a rare multisystem autoimmune disease characterized by fibrosis, vasculopathy, and autoimmunity. There are multiple complications inherent to SSc and its management. One of these complications is increased infection risk, which can lead to decreased quality of life and increased morbidity and mortality. Patients with SSc have lower vaccination rates and decreased vaccine seroconversion secondary to immunosuppressive medications compared with the general population. The purpose of this review is to provide clinicians with an approach to vaccinations in SSc.
Collapse
Affiliation(s)
- Leonardo Martin Calderon
- Department of Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada
| | - Janet E Pope
- Department of Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada; Division of Rheumatology, St. Joseph's Health Care, London, Ontario, Canada
| | - Ami A Shah
- Division of Rheumatology, Johns Hopkins University School of Medicine, Johns Hopkins Scleroderma Center, Baltimore, MD, USA
| | - Robyn T Domsic
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, 3500 Terrace Street, Pittsburgh, PA 15261, USA.
| |
Collapse
|
8
|
Domsic RT, Medsger TA, Gao S, Laffoon M, Huang S, Wisniewski S, Spino C, Steen V, Lafyatis R, Khanna D. A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials. Rheumatology (Oxford) 2023; 62:1543-1551. [PMID: 36031807 PMCID: PMC10072884 DOI: 10.1093/rheumatology/keac501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Revised: 07/27/2022] [Accepted: 07/29/2022] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVE Clinical trials in early diffuse SSc have consistently shown a placebo group response with a declining modified Rodnan skin score (mRSS), with negative outcomes. Our objective was to identify strategies using clinical characteristics or laboratory values to improve trial design. METHODS We identified early diffuse SSc patients first seen at the University of Pittsburgh from 1980-2015. Eligible patients had ≥3 visits, with at least two mRSS scores within the first year of follow-up. We performed Kaplan-Meier analyses, group-based trajectory analysis of mRSS scores, followed by multivariable regression analysis and classification tree analysis. We applied the results to the abatacept in early diffuse systemic sclerosis (ASSET) trial outcome data. RESULTS We identified 403 patients with <18 months, and 514 with <36 months disease duration. The median number of mRSS follow-up scores was 14 (interquartile range 8, 25). All methodologic approaches identified skin thickness progression rate, RNA polymerase III (RNAP3) antibody positivity and presence of tendon friction rubs (TFR) as predictors of mRSS trajectory over 5 years of follow-up, and thereby as potential enrichment variables. When applied to the ASSET data, adjustment for both RNAP3 and TFR demonstrated reduction of the placebo mRSS response, particularly at 6 months. A significant difference in the ACR Composite Response Index in Systemic Sclerosis (CRISS) score was found with adjustment by RNAP3 at 6 months, and TFR or RNAP3 at 12 months. CONCLUSION Adjustment for both RNAP3 and TFR predicts mRSS trajectory and diminished the mRSS decline in ASSET placebo group, and identified significant differences in CRISS. RNAP3, particularly, is a stratification or enrichment approach to improve early diffuse SSc trial design.
Collapse
Affiliation(s)
- Robyn T Domsic
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Thomas A Medsger
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Shiyao Gao
- Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA
| | - Maureen Laffoon
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Suiyuan Huang
- Division of Rheumatology, Department of Internal Medicine and Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA
| | - Stephen Wisniewski
- Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA
| | - Cathie Spino
- Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA
| | - Virginia Steen
- Division of Rheumatology, Department of Medicine, Georgetown University, Washington, DC, USA
| | - Robert Lafyatis
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Dinesh Khanna
- Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
| |
Collapse
|
9
|
Domsic RT, Pokrzywinski R, Stassek L, Benton WW, Vampola CL, Furst DE, Chung L, Steen V, Mayes MD, Shah AA, Molitor JA, Oliver K, Nagaraja V, Khanna D. Qualitative Interviews to Assess the Content Validity and Usability of the Electronic Raynaud Diary in Patients with Systemic Sclerosis. ACR Open Rheumatol 2023; 5:132-141. [PMID: 36727567 PMCID: PMC10010488 DOI: 10.1002/acr2.11522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Revised: 08/17/2022] [Accepted: 09/04/2022] [Indexed: 02/03/2023] Open
Abstract
OBJECTIVE To better understand the symptoms and impacts of Raynaud phenomenon (RP) in patients with systemic sclerosis (SSc) and to evaluate the content validity and usability of a new electronic patient-reported outcome (PRO) measure for RP: the Raynaud Diary. METHODS The Raynaud Diary was developed as a daily eDiary for assessing the number and duration of symptomatic Raynaud attacks; worst pain, numbness, tingling, and discomfort in the fingers; and overall disease severity, captured using the Raynaud's Condition Score. The Raynaud Diary was debriefed in two waves of qualitative interviews with adults with self-reported RP secondary to SSc. All interviews included open-ended questions about participants' experiences of RP. RESULTS Participants (N = 39) had a mean age of 55.1 years, and 87% were female. Frequently reported RP symptoms were color change (reported by all participants), numbness (90%), tingling (82%), pain (77%), and discomfort (72%). Common attack triggers included temperature-related factors and stress. Participants reported being unable to be outside or do outdoor activities and had problems gripping objects. All participants demonstrated understanding of the Raynaud Diary instructions. Most participants indicated that they would be able to use the Raynaud Diary to record the worst severity of individual RP symptoms in the previous 24 hours. CONCLUSION Patients with RP secondary to SSc bear a heavy symptom burden. The Raynaud Diary is a content valid PRO measure that captures the most frequent symptoms of RP in patients with SSc.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Ami A Shah
- Johns Hopkins University School of Medicine, Maryland, Baltimore
| | | | | | - Vivek Nagaraja
- University of Michigan Scleroderma Program, Ann Arbor, Michigan
| | - Dinesh Khanna
- Eicos Sciences, Inc., San Mateo, California, and University of Michigan Scleroderma Program, Ann Arbor, Michigan
| |
Collapse
|
10
|
Chen L, Zhao J, Chao Y, Roy A, Guo W, Qian J, Xu W, Domsic RT, Lafyatis R, Lu B, Deng F, Wang QJ. Loss of Protein Kinase D2 Activity Protects Against Bleomycin-Induced Dermal Fibrosis in Mice. J Transl Med 2023; 103:100018. [PMID: 37039152 PMCID: PMC10507682 DOI: 10.1016/j.labinv.2022.100018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2022] [Revised: 08/22/2022] [Accepted: 09/20/2022] [Indexed: 01/11/2023] Open
Abstract
Protein kinase D (PKD) has been linked to inflammatory responses in various pathologic conditions; however, its role in inflammation-induced dermal fibrosis has not been evaluated. In this study, we aimed to investigate the roles and mechanisms of protein kinase D2 (PKD2) in inflammation-induced dermal fibrosis and evaluate the therapeutic potential of PKD inhibitors in this disease. Using homozygous kinase-dead PKD2 knock-in (KI) mice, we examined whether genetic ablation or pharmacologic inhibition of PKD2 activity affected dermal inflammation and fibrosis in a bleomycin (BLM)-induced skin fibrosis model. Our data showed that dermal thickness and collagen fibers were significantly reduced in BLM-treated PKD2 KI mice compared with that in wild-type mice, and so was the expression of α-smooth muscle actin and collagens and the mRNA levels of transforming growth factor-β1 and interleukin-6 in the KI mice. Corroboratively, pharmacologic inhibition of PKD by CRT0066101 also significantly blocked BLM-induced dermal fibrosis and reduced α-smooth muscle actin, collagen, and interleukin-6 expression. Further analyses indicated that loss of PKD2 activity significantly blocked BLM-induced infiltration of monocytes/macrophages and neutrophils in the dermis. Moreover, using bone marrow-derived macrophages, we demonstrated that PKD activity was required for cytokine production and migration of macrophages. We have further identified Akt as a major downstream target of PKD2 in the early inflammatory phase of the fibrotic process. Taken together, our findings indicate that PKD2 promotes dermal fibrosis via regulating immune cell infiltration, cytokine production, and downstream activation of Akt in lesional skin, and targeted inhibition of PKD2 may benefit the treatment of this condition.
Collapse
Affiliation(s)
- Liping Chen
- Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
| | - Jinjun Zhao
- Department of Rheumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Yapeng Chao
- Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Adhiraj Roy
- Amity Institute of Molecular Medicine and Stem Cell Research, Amity University, Noida, India
| | - Wenjing Guo
- Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
| | - Jiabi Qian
- Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
| | - Wanfu Xu
- Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
| | - Robyn T Domsic
- Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Robert Lafyatis
- Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Binfeng Lu
- Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Fan Deng
- Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
| | - Q Jane Wang
- Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.
| |
Collapse
|
11
|
Rahaghi FF, Hsu VM, Kaner RJ, Mayes MD, Rosas IO, Saggar R, Steen VD, Strek ME, Bernstein EJ, Bhatt N, Castelino FV, Chung L, Domsic RT, Flaherty KR, Gupta N, Kahaleh B, Martinez FJ, Morrow LE, Moua T, Patel N, Shlobin OA, Southern BD, Volkmann ER, Khanna D. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease. Respir Res 2023; 24:6. [PMID: 36624431 PMCID: PMC9830797 DOI: 10.1186/s12931-022-02292-3] [Citation(s) in RCA: 29] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Accepted: 12/13/2022] [Indexed: 01/11/2023] Open
Abstract
BACKGROUND Systemic sclerosis (SSc) is a rare, complex, connective tissue disorder. Interstitial lung disease (ILD) is common in SSc, occurring in 35-52% of patients and accounting for 20-40% of mortality. Evolution of therapeutic options has resulted in a lack of consensus on how to manage this condition. This Delphi study was initiated to develop consensus recommendations based on expert physician insights regarding screening, progression, treatment criteria, monitoring of response, and the role of recent therapeutic advances with antifibrotics and immunosuppressants in patients with SSc-ILD. METHODS A modified Delphi process was completed by pulmonologists (n = 13) and rheumatologists (n = 12) with expertise in the management of patients with SSc-ILD. Panelists rated their agreement with each statement on a Likert scale from - 5 (complete disagreement) to + 5 (complete agreement). Consensus was predefined as a mean Likert scale score of ≤ - 2.5 or ≥ + 2.5 with a standard deviation not crossing zero. RESULTS Panelists recommended that all patients with SSc be screened for ILD by chest auscultation, spirometry with diffusing capacity of the lungs for carbon monoxide, high-resolution computed tomography (HRCT), and/or autoantibody testing. Treatment decisions were influenced by baseline and changes in pulmonary function tests, extent of ILD on HRCT, duration and degree of dyspnea, presence of pulmonary hypertension, and potential contribution of reflux. Treatment success was defined as stabilization or improvement of signs or symptoms of ILD and functional status. Mycophenolate mofetil was identified as the initial treatment of choice. Experts considered nintedanib a therapeutic option in patients with progressive fibrotic ILD despite immunosuppressive therapy or patients contraindicated/unable to tolerate immunotherapy. Concomitant use of nintedanib with MMF/cyclophosphamide can be considered in patients with advanced disease at initial presentation, aggressive ILD, or significant disease progression. Although limited consensus was achieved on the use of tocilizumab, the experts considered it a therapeutic option for patients with early SSc and ILD with elevated acute-phase reactants. CONCLUSIONS This modified Delphi study generated consensus recommendations for management of patients with SSc-ILD in a real-world setting. Findings from this study provide a management algorithm that will be helpful for treating patients with SSc-ILD and addresses a significant unmet need.
Collapse
Affiliation(s)
- Franck F. Rahaghi
- grid.418628.10000 0004 0481 997XRespiratory Center, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331 USA
| | | | - Robert J. Kaner
- grid.5386.8000000041936877XWeill Cornell Medicine, New York, NY USA
| | - Maureen D. Mayes
- grid.267308.80000 0000 9206 2401University of Texas, Houston, TX USA
| | - Ivan O. Rosas
- grid.62560.370000 0004 0378 8294Brigham and Women’s Hospital, Boston, MA USA
| | - Rajan Saggar
- grid.19006.3e0000 0000 9632 6718University of California Los Angeles, Los Angeles, CA USA
| | - Virginia D. Steen
- grid.213910.80000 0001 1955 1644Georgetown University, Washington, D.C USA
| | - Mary E. Strek
- grid.170205.10000 0004 1936 7822University of Chicago, Chicago, IL USA
| | - Elana J. Bernstein
- grid.239585.00000 0001 2285 2675Columbia University Irving Medical Center, New York, NY USA
| | - Nitin Bhatt
- grid.261331.40000 0001 2285 7943Ohio State University, Columbus, OH USA
| | | | - Lorinda Chung
- grid.168010.e0000000419368956Stanford University School of Medicine and Palo Alto VA Health Care System, Stanford, CA USA
| | - Robyn T. Domsic
- grid.412689.00000 0001 0650 7433University of Pittsburgh Medical Center, Pittsburgh, PA USA
| | - Kevin R. Flaherty
- grid.214458.e0000000086837370University of Michigan Scleroderma Clinic, Ann Arbor, MI 48105 USA
| | - Nishant Gupta
- grid.24827.3b0000 0001 2179 9593University of Cincinnati, Cincinnati, OH USA
| | - Bashar Kahaleh
- grid.411726.70000 0004 0628 5895University of Toledo Medical Center, Toledo, OH USA
| | | | - Lee E. Morrow
- grid.254748.80000 0004 1936 8876Creighton University, Omaha, NE USA
| | - Teng Moua
- grid.66875.3a0000 0004 0459 167XMayo Clinic, Rochester, MN USA
| | - Nina Patel
- grid.239585.00000 0001 2285 2675Columbia University Irving Medical Center, New York, NY USA ,grid.418412.a0000 0001 1312 9717Present Address: Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT USA
| | - Oksana A. Shlobin
- grid.417781.c0000 0000 9825 3727Inova Fairfax Hospital, Falls Church, VA USA
| | | | - Elizabeth R. Volkmann
- grid.19006.3e0000 0000 9632 6718University of California Los Angeles, Los Angeles, CA USA
| | - Dinesh Khanna
- grid.214458.e0000000086837370University of Michigan Scleroderma Clinic, Ann Arbor, MI 48105 USA
| |
Collapse
|
12
|
Yu L, Domsic RT, Saketkoo LA, Withey J, Frech TM, Herrick AL, Hummers LK, Shah AA, Denton CP, Khanna D, Pauling JD. Assessment of the Systemic Sclerosis-Associated Raynaud's Phenomenon Questionnaire: Item Bank and Short-Form Development. Arthritis Care Res (Hoboken) 2022. [PMID: 36214062 DOI: 10.1002/acr.25038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Revised: 09/12/2022] [Accepted: 10/04/2022] [Indexed: 01/31/2023]
Abstract
OBJECTIVE To develop, refine, and score a novel patient-reported outcome instrument to assess the severity and impact of Raynaud's phenomenon (RP) in systemic sclerosis (SSc). METHODS The Assessment of Systemic Sclerosis-Associated Raynaud's Phenomenon (ASRAP) questionnaire items were developed with patient insight partner support and grounded in the lived patient experience of SSc-RP. ASRAP items underwent formal qualitative assessment and linguistic testing. An international multicenter study was undertaken to field test the preliminary ASRAP questionnaire. RESULTS A preliminary 37-item ASRAP questionnaire was supplemented with 2 additional items following expert review to enhance content coverage before undergoing formal linguistic testing to optimize readability. Patient cognitive debriefing interviews were undertaken to enhance comprehension, ambiguity, cognitive difficulty, relevance, and content coverage of both the ASRAP items and instructions. We enrolled 420 SSc patients from scleroderma centers in the UK and US over 2 consecutive winters. Factor analysis with item response theory was undertaken to remove redundant and poorly fitting items. The retained 27-item long-form ASRAP questionnaire was calibrated and scored using the graded response model. A fixed 10-item short-form ASRAP questionnaire was developed using computerized adaptive testing simulations. CONCLUSION The ASRAP questionnaire has been developed with extensive SSc patient input, with items grounded in the lived experience of SSc-RP to ensure strong content validity, with a focus on how patients feel and function. An advanced psychometric approach with expert input has removed redundant and/or poorly fitting items without eroding content validity. Long- and short-form ASRAP questionnaires have been calibrated and scored to permit formal validation.
Collapse
Affiliation(s)
- Lan Yu
- University of Pittsburgh, Pittsburgh, Pennsylvania
| | | | | | - Jane Withey
- Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Bath, UK
| | | | - Ariane L Herrick
- The University of Manchester, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, and NIHR Manchester Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester, UK, and Salford Royal NHS Foundation Trust, Salford, UK
| | - Laura K Hummers
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Ami A Shah
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | | | | | - John D Pauling
- Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Bath, UK, and North Bristol NHS Trust and University of Bristol, Bristol, UK
| |
Collapse
|
13
|
Suresh S, Charlton D, Snell EK, Laffoon M, Medsger TA, Zhu L, Domsic RT. Development of Pulmonary Hypertension in Over One-Third of Patients With Th/To Antibody-Positive Scleroderma in Long-Term Follow-Up. Arthritis Rheumatol 2022; 74:1580-1587. [PMID: 35467794 PMCID: PMC9477491 DOI: 10.1002/art.42152] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Revised: 03/15/2022] [Accepted: 04/19/2022] [Indexed: 11/05/2022]
Abstract
OBJECTIVE This study was undertaken to describe clinical manifestations in patients with Th/To antibody-positive systemic sclerosis (SSc) during long-term follow-up. METHODS We performed a case-control study involving anti-Th/To antibody-positive patients with SSc who were newly referred to the University of Pittsburgh Medical Center and the Pittsburgh Scleroderma Center from 1980 to 2015. For every case, 2 anti-Th/To antibody-negative SSc patients (the first 2 consecutively seen after a case) were used as controls. Long-term disease manifestations and survival were then compared between cases and controls. RESULTS A total of 204 anti-Th/To antibody-positive SSc patients and 408 controls were identified. The cohort had a mean ± SD age of 52 ± 12.9 years, and 76% of individuals were women. Anti-Th/To antibody-positive patients more often presented without skin thickening (P < 0.0001) and had a higher rate of pulmonary hypertension (PH) (P < 0.0001) and interstitial lung disease (P = 0.05) compared to anti-Th/To antibody-negative SSc controls. Anti-Th/To antibody-positive SSc patients also had less frequent muscle and joint involvement than anti-Th/To antibody-negative SSc controls (P < 0.0001). After a median clinical follow-up period of 6.1 years (interquartile range 2.4-12.7), 38% of anti-Th/To-positive patients had developed PH compared to 15% of anti-Th/To antibody-negative SSc controls (P < 0.0001). The rate of PH classified as World Health Organization (WHO) Group 1 pulmonary arterial hypertension [PAH] was 23% in anti-Th/To-positive patients compared to 9% in anti-Th/To antibody-negative SSc controls (P < 0.0001). After adjusting for age and sex, anti-Th/To antibody positivity was associated with a hazard ratio (HR) of 3.3 (95% confidence interval 2.3-4.9) for increased risk of developing PH at 10 years of follow-up from the first scleroderma center visit. CONCLUSION This is the largest cohort of patients with anti-Th/To antibody-positive SSc with long-term follow-up data. The very high rate (38%) and associated independent risk of anti-Th/To antibody-positive patients developing PH in follow-up, particularly in WHO Group 1 PAH patients, is striking. Patients presenting with limited skin involvement should be tested for Th/To antibodies, and if present, careful monitoring for PH is warranted.
Collapse
Affiliation(s)
| | - Devon Charlton
- Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine
| | | | - Maureen Laffoon
- Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine
| | - Thomas A. Medsger
- Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine
| | - Lei Zhu
- Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine
| | - Robyn T. Domsic
- Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine
| |
Collapse
|
14
|
Van Meerbeke SW, Fajt ML, Marini RV, Domsic RT, Petrov AA. Antibody response to graded dosing of coronavirus disease 2019 messenger RNA vaccines after allergic reaction to first dose. Ann Allergy Asthma Immunol 2022; 129:373-374. [PMID: 35595005 PMCID: PMC9112645 DOI: 10.1016/j.anai.2022.05.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Revised: 05/08/2022] [Accepted: 05/09/2022] [Indexed: 12/26/2022]
Affiliation(s)
- Sara W Van Meerbeke
- Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| | - Merritt L Fajt
- Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| | - Rachel V Marini
- Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| | - Robyn T Domsic
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| | - Andrej A Petrov
- Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
| |
Collapse
|
15
|
Khanna D, Caldron P, Martin RW, Kafaja S, Spiera R, Shahouri S, Shah A, Hsu V, Ervin J, Simms R, Domsic RT, Steen V, Hummers LK, Derk C, Mayes M, Chatterjee S, Varga J, Kesten S, Fraser JK, Furst DE. Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial. Arthritis Rheumatol 2022; 74:1399-1408. [PMID: 35358372 PMCID: PMC9544105 DOI: 10.1002/art.42133] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Revised: 02/08/2022] [Accepted: 03/25/2022] [Indexed: 11/25/2022]
Abstract
Objective Hand dysfunction is common in systemic sclerosis (SSc). We undertook this study to evaluate the capacity of autologous adipose‐derived regenerative cells (ADRCs) to improve hand function in SSc patients. Methods The Scleroderma Treatment with Celution Processed Adipose Derived Regenerative Cells Trial was a prospective, randomized, double‐blind trial of ADRCs, in which ADRCs were obtained from patients with SSc by small‐volume adipose tissue harvest, and the fingers of each patient were injected with ADRCs. The primary end point was change in hand function at 24 and 48 weeks, assessed using the Cochin Hand Function Scale (CHFS). One of the secondary end points included the change in Health Assessment Questionnaire disability index (HAQ DI) at 48 weeks. Separate prespecified analyses were performed for patients with diffuse cutaneous SSc (dcSSc) and those with limited cutaneous SSc (lcSSc). Results Eighty‐eight patients were randomized to receive ADRCs (n = 48 [32 patients with dcSSc and 16 with lcSSc]) or placebo (n = 40 [19 patients with dcSSc and 21 with lcSSc]). Change in hand function according to CHFS score was numerically higher for the ADRC group compared to the placebo group but did not achieve statistical significance (mean ± SD improvement in the CHFS score at 48 weeks 11.0 ± 12.5 versus 8.9 ± 10.5; P = 0.299). For patients with dcSSc, the between‐group difference in the CHFS at 48 weeks was 6.3 points (nominal P = 0.069). For the secondary end point, the dcSSc group exhibited a between‐group difference of 0.17 points in the HAQ DI (nominal P = 0.044) at 48 weeks. Of the ADRC‐treated patients with dcSSc, 52% reported improvement greater than the minimum clinically important difference for both CHFS and HAQ DI compared to 16% in the placebo group (nominal P = 0.016). Small‐volume adipose tissue harvest and ADRC treatment were well tolerated. Conclusion While the primary end point of this trial was not achieved, efficacy trends were observed in patients with dcSSc. Adipose tissue harvest and ADRC injection were demonstrated to be feasible. Further clinical trials of this intervention in the setting of dcSSc are warranted.
Collapse
Affiliation(s)
| | - Paul Caldron
- Arizona Arthritis & Rheumatology Research, Phoenix
| | | | | | | | | | - Ankoor Shah
- Duke University Medical Center, Durham, North Carolina
| | - Vivien Hsu
- Rutgers University, New Brunswick, New Jersey
| | - John Ervin
- Alliance for Multispecialty Research, Kansas City, Missouri
| | - Robert Simms
- Boston University Medical Center, Boston, Massachusetts
| | | | | | | | - Chris Derk
- University of Pennsylvania, Philadelphia
| | | | - Soumya Chatterjee
- Cleveland Clinic Orthopedic & Rheumatologic Institute, Cleveland, Ohio
| | - John Varga
- Northwestern University, Chicago, Illinois, and University of Michigan, Ann Arbor
| | | | | | | |
Collapse
|
16
|
Domsic RT, Gao S, Laffoon M, Wisniewski S, Zhang Y, Steen V, Lafyatis R, Medsger TA. Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design. Rheumatology (Oxford) 2021; 60:4662-4670. [PMID: 33506859 PMCID: PMC8677444 DOI: 10.1093/rheumatology/keab075] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Revised: 12/15/2020] [Indexed: 12/21/2022] Open
Abstract
OBJECTIVES Clinical trials in early diffuse cutaneous systemic sclerosis (SSc) using the modified Rodnan skin score (mRSS) as the primary outcome measure have most often been negative. We wanted to assess how the definition of disease onset (first SSc manifestation vs first non-Raynaud manifestation) and varying lengths of disease duration at trial entry as an inclusion criteria functioned. Our objective was to optimize trial inclusion criteria. METHODS We used the prospective, observational University of Pittsburgh Scleroderma Cohort to identify early diffuse SSc patients first evaluated between 1980 and 2015. All had <3 years from first SSc (n = 481) or first non-Raynaud manifestation (n = 514) and three or more mRSS scores. We used descriptive, survival and group-based trajectory analyses to compare the different definitions of disease onset and disease duration as inclusion criteria for clinical trials. RESULTS There was no appreciable difference between using first SSc manifestation compared with first non-Raynaud manifestation as the definition of disease onset. Compared with other disease durations, <18 months of disease had >70% of patients fitting into trajectories with worsening cutaneous disease over 6 months of follow-up. Longer disease durations demonstrated the majority of patients with trajectories showing an improvement in mRSS (regression to the mean) over 6 months. CONCLUSIONS Regardless of whether the first SSc or first non-Raynaud manifestation is used to define disease onset, duration of <18 months at enrolment is preferable. A longer disease duration criterion more frequently results in regression to the mean of the mRSS score, and likely contributes to negative trial outcomes.
Collapse
Affiliation(s)
- Robyn T Domsic
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine
| | - Shiyao Gao
- Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA
| | - Maureen Laffoon
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine
| | - Steven Wisniewski
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine
| | - Yuqing Zhang
- Division of Epidemiology, Massachusetts General Hospital, Boston, MA
| | - Virginia Steen
- Division of Rheumatology, Georgetown University, Washington, DC, USA
| | - Robert Lafyatis
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine
| | - Thomas A Medsger
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine
| |
Collapse
|
17
|
Kong K, Koontz D, Morse C, Roth E, Domsic RT, Simon MA, Stratton E, Buchholz C, Tobin-Finch K, Simms R, George MP, Hassoun PM, Farber H, Lafyatis R. A Pilot Study of Dimethyl Fumarate in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis. J Scleroderma Relat Disord 2021; 6:242-246. [PMID: 35005243 DOI: 10.1177/23971983211016196] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Introduction Given the poor treatment options for pulmonary arterial hypertension associated systemic sclerosis (SSc-PAH) patients, we sought to determine clinical safety and efficacy of Dimethylfumarate (DMF), an Nrf2 agonist, and the effects on biomarkers of oxidative stress on SSc-PAH in an exploratory interventional clinical trial. Objectives The primary objectives were to assess the safety and efficacy of treatment with DMF in patients with SSc-PAH. Methods This was an investigator-initiated, double-blind, randomized, placebo-controlled trial conducted at two sites in the United States. The primary safety endpoint was the incidence of serious adverse events (SAEs) and all adverse events (AEs) in DMF compared to placebo-treated patients. The primary efficacy endpoint was the change in 6MWD from baseline to the end of treatment at Week 24 in DMF compared to placebo-treated patients. Results Six participants were randomized to either placebo (n = 2) or DMF (n = 4). Baseline demographics were similar in both groups. A total of 25 adverse events (AEs) occurred in 6 subjects, with 14 AEs (56.0%) having occurred in DMF-treated subjects. 3 occurrences were identified as nausea AEs, and two participants withdrew due to nausea. One participant in the placebo group was withdrawn after a hospitalization SAE due to worsening of heart failure and shortness of breath secondary to anemia. One participant in each group completed protocol. Subjects in the DMF-treated group showed a non-significant reduced decline in 6MWD (relative mean change of -7.07%) from baseline to Week 24 as compared to placebo-treated subjects (relative mean change of -14.97%). Conclusion Patients treated for SSc-PAH with 2 and 3-drug regimens, as is now typical for these patients, tolerate DMF poorly. Our small samples size did not provide power to suggest efficacy. We suggest that Nrf2 is still a valid therapeutic target for future trials, using better tolerated Nrf2 agonists.
Collapse
Affiliation(s)
- Kristi Kong
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
| | - Diane Koontz
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
| | - Christina Morse
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
| | - Eileen Roth
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
| | - Robyn T Domsic
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
| | - Marc A Simon
- Division of Cardiology, University of Pittsburgh, Pittsburgh, PA
| | - Eric Stratton
- Division of Rheumatology, Arthritis Center, Boston University, Boston, MA
| | - Connor Buchholz
- Division of Rheumatology, Arthritis Center, Boston University, Boston, MA
| | | | - Robert Simms
- Division of Rheumatology, Arthritis Center, Boston University, Boston, MA
| | - M Patricia George
- Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO
| | - Paul M Hassoun
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD
| | - Harrison Farber
- Division of Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Boston, MA
| | - Robert Lafyatis
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
| |
Collapse
|
18
|
Crespo MM, Claridge T, Domsic RT, Hartwig M, Kukreja J, Stratton K, Chan KM, Molina M, Ging P, Cochrane A, Hoetzenecker K, Ahmad U, Kapnadak S, Timofte I, Verleden G, Lyu D, Quddus S, Davis N, Porteous M, Mallea J, Perch M, Distler O, Highland K, Magnusson J, Vos R, Glanville AR. ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements. J Heart Lung Transplant 2021; 40:1279-1300. [PMID: 34474940 DOI: 10.1016/j.healun.2021.07.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Accepted: 07/22/2021] [Indexed: 12/18/2022] Open
Abstract
Patients with connective tissues disease (CTD) are often on immunomodulatory agents before lung transplantation (LTx). Till now, there's no consensus on the safety of using these agents perioperative and post-transplant. The International Society for Heart and Lung Transplantation-supported consensus document on LTx in patients with CTD addresses the risk and contraindications of perioperative and post-transplant management of the biologic disease-modifying antirheumatic drugs (bDMARD), kinase inhibitor DMARD, and biologic agents used for LTx candidates with underlying CTD, and the recommendations and management of non-gastrointestinal extrapulmonary manifestations, and esophageal disorders by medical and surgical approaches for CTD transplant recipients.
Collapse
Affiliation(s)
- Maria M Crespo
- Division of Pulmonary, Allergy and Critical Care Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
| | - Tamara Claridge
- Department of Pharmacy, Hospital of the University of University of Pennsylvania, Philadelphia, Pennsylvania
| | - Robyn T Domsic
- Division of Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| | - Matthew Hartwig
- Division of Thoracic Surgery, Duke University Medical Center, Durham, North Carolina
| | - Jasleen Kukreja
- Division of Thoracic Surgery, University of California San Francisco, San Francisco, California
| | - Kathleen Stratton
- Department of Pharmacy, Hospital of the University of University of Pennsylvania, Philadelphia, Pennsylvania
| | - Kevin M Chan
- Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor, Michigan
| | - Maria Molina
- Department of Pharmacy, Hospital of the University of University of Pennsylvania, Philadelphia, Pennsylvania
| | - Patricia Ging
- Department of Pharmacy, Mater Misericordiae University Hospital, Dublin, Ireland
| | - Adam Cochrane
- Department of Pharmacy, Inova Fairfax Hospital, Falls Church, Virginia
| | - Konrad Hoetzenecker
- Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria
| | - Usman Ahmad
- Department of Cardiothoracic Surgery, Cleveland Clinic, Cleveland, Ohio
| | - Siddhartha Kapnadak
- Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, Washington
| | - Irina Timofte
- Division of Pulmonary, University of Maryland Medical System, Baltimore, Maryland
| | - Geert Verleden
- Lung Transplant Unit, University Hospital of Gasthuisberg, Leuven, Belgium
| | - Dennis Lyu
- Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor, Michigan
| | - Sana Quddus
- Division of Pulmonary and Critical Care Medicine, Loyola University Medical Center, Stritch School of Medicine, Maywood, Illinois
| | - Nicole Davis
- Lung Transplant Program, Tampa General Hospital, Tampa, Florida
| | - Mary Porteous
- Division of Pulmonary, Allergy and Critical Care Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
| | - Jorge Mallea
- Division of Pulmonary, Allergy, and Critical Care, Mayo Clinic Florida, Jacksonville, Florida
| | - Michael Perch
- Lung Transplant Program, Rigshospitalet, Copenhagen, Denmark
| | - Olivier Distler
- Department of Rheumatology, University of Zurich Medical Center, Zurich, Switzerland
| | | | - Jesper Magnusson
- Department of Pulmonology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Robin Vos
- Lung Transplant Unit, University Hospital of Gasthuisberg, Leuven, Belgium
| | - Allan R Glanville
- The Lung Transplant Unit, St. Vincent's Hospital, Sydney, New South Wales, Australia
| |
Collapse
|
19
|
Zamanian RT, Pinckney A, Domsic RT, Medsger T, Keyes-Elstein L, Sweatt AJ, Welch B, Goldmuntz E, Nicolls MR, Chung L. Reply to Andréasson et al.: Multiple Manifestations of Systemic Sclerosis Affect Walk Distance. Am J Respir Crit Care Med 2021; 204:377-378. [PMID: 34107229 PMCID: PMC8513578 DOI: 10.1164/rccm.202104-1023le] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- Roham T Zamanian
- Stanford University School of Medicine Stanford, California.,Vera Moulton Wall Center for Pulmonary Vascular Disease Stanford, California
| | | | - Robyn T Domsic
- University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania
| | - Thomas Medsger
- University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania
| | | | - Andrew J Sweatt
- Stanford University School of Medicine Stanford, California.,Vera Moulton Wall Center for Pulmonary Vascular Disease Stanford, California
| | - Beverly Welch
- National Institute of Allergy and Infectious Diseases Bethesda, Maryland
| | - Ellen Goldmuntz
- National Institute of Allergy and Infectious Diseases Bethesda, Maryland
| | - Mark R Nicolls
- Stanford University School of Medicine Stanford, California.,Vera Moulton Wall Center for Pulmonary Vascular Disease Stanford, California.,Veterans Affairs Palo Alto Health Care System Palo Alto, California
| | - Lorinda Chung
- Stanford University School of Medicine Stanford, California.,Veterans Affairs Palo Alto Health Care System Palo Alto, California
| |
Collapse
|
20
|
Assassi S, Li N, Volkmann ER, Mayes MD, Rünger D, Ying J, Roth MD, Hinchcliff M, Khanna D, Frech T, Clements PJ, Furst DE, Goldin J, Bernstein EJ, Castelino FV, Domsic RT, Gordon JK, Hant FN, Shah AA, Shanmugam VK, Steen VD, Elashoff RM, Tashkin DP. Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease. Arthritis Rheumatol 2021; 73:1005-1013. [PMID: 33350170 DOI: 10.1002/art.41627] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Accepted: 12/15/2020] [Indexed: 01/15/2023]
Abstract
OBJECTIVE Response to immunosuppression is highly variable in systemic sclerosis (SSc)-related interstitial lung disease (ILD). This study was undertaken to determine whether a composite serum interferon (IFN)-inducible protein score exhibits predictive significance for the response to immunosuppression in SSc-ILD. METHODS Serum samples collected in the Scleroderma Lung Study II, a randomized controlled trial of mycophenolate mofetil (MMF) versus cyclophosphamide (CYC), were examined. Results were validated in an independent observational cohort receiving active treatment. A composite score of 6 IFN-inducible proteins IFNγ-inducible 10-kd protein, monokine induced by IFNγ, monocyte chemotactic protein 2, β2 -microglobulin, tumor necrosis factor receptor type II, and macrophage inflammatory protein 3β) was calculated, and its predictive significance for longitudinal forced vital capacity percent predicted measurements was evaluated. RESULTS Higher baseline IFN-inducible protein score predicted better response over 3 to 12 months in the MMF arm (point estimate = 0.41, P = 0.001) and CYC arm (point estimate = 0.91, P = 0.009). In contrast, higher baseline C-reactive protein (CRP) levels were predictive of a worse ILD course in both treatment arms. The predictive significance of the IFN-inducible protein score and CRP levels remained after adjustment for baseline demographic and clinical predictors. During the second year of treatment, in which patients in the CYC arm were switched to placebo, a higher IFN-inducible protein score at 12 months showed a trend toward predicting a worse ILD course (point estimate = -0.61, P = 0.068), while it remained predictive of better response to active immunosuppression in the MMF arm (point estimate = 0.28, P = 0.029). The predictive significance of baseline IFN-inducible protein score was replicated in the independent cohort (rs = 0.43, P = 0.028). CONCLUSION A higher IFN-inducible protein score in SSc-ILD is predictive of better response to immunosuppression and could potentially be used to identify patients who may derive the most benefit from MMF or CYC.
Collapse
Affiliation(s)
| | - Ning Li
- University of California, Los Angeles
| | | | | | | | - Jun Ying
- University of Texas Health Science Center at Houston
| | | | | | | | | | | | | | | | | | - Flavia V Castelino
- Massachusetts General Hospital and Harvard University, Boston, Massachusetts
| | | | | | - Faye N Hant
- Medical University of South Carolina, Charleston
| | - Ami A Shah
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | | | | | | | | |
Collapse
|
21
|
Zamanian RT, Badesch D, Chung L, Domsic RT, Medsger T, Pinckney A, Keyes-Elstein L, D'Aveta C, Spychala M, White RJ, Hassoun PM, Torres F, Sweatt AJ, Molitor JA, Khanna D, Maecker H, Welch B, Goldmuntz E, Nicolls MR. Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. Am J Respir Crit Care Med 2021; 204:209-221. [PMID: 33651671 PMCID: PMC8650794 DOI: 10.1164/rccm.202009-3481oc] [Citation(s) in RCA: 60] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Rationale: Systemic sclerosis (SSc)-pulmonary arterial hypertension (PAH) is one of the most prevalent and deadly forms of PAH. B cells may contribute to SSc pathogenesis. Objectives: We investigated the safety and efficacy of B-cell depletion for SSc-PAH. Methods: In an NIH-sponsored, multicenter, double-blinded, randomized, placebo-controlled, proof-of-concept trial, 57 patients with SSc-PAH on stable-dose standard medical therapy received two infusions of 1,000 mg rituximab or placebo administered 2 weeks apart. The primary outcome measure was the change in 6-minute-walk distance (6MWD) at 24 weeks. Secondary endpoints included safety and invasive hemodynamics. We applied a machine learning approach to predict drug responsiveness. Measurements and Main Results: We randomized 57 subjects from 2010 to 2018. In the primary analysis, using data through Week 24, the adjusted mean change in 6MWD at 24 weeks favored the treatment arm but did not reach statistical significance (23.6 ± 11.1 m vs. 0.5 ± 9.7 m; P = 0.12). Although a negative study, when data through Week 48 were also considered, the estimated change in 6MWD at Week 24 was 25.5 ± 8.8 m for rituximab and 0.4 ± 7.4 m for placebo (P = 0.03). Rituximab treatment appeared to be safe and well tolerated. Low levels of RF (rheumatoid factor), IL-12, and IL-17 were sensitive and specific as favorable predictors of a rituximab response as measured by an improved 6MWD (receiver operating characteristic area under the curve, 0.88-0.95). Conclusions: B-cell depletion therapy is a potentially effective and safe adjuvant treatment for SSc-PAH. Future studies in these patients can confirm whether the identified biomarkers predict rituximab responsiveness. Clinical trial registered with www.clinicaltrails.gov (NCT01086540).
Collapse
Affiliation(s)
- Roham T Zamanian
- Division of Pulmonary, Allergy, and Critical Care Medicine and.,Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford, California
| | - David Badesch
- Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado
| | - Lorinda Chung
- Division of Pulmonary, Allergy, and Critical Care Medicine and.,Division of Rheumatology and Immunology, Stanford University, Stanford University School of Medicine, Stanford, California
| | - Robyn T Domsic
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
| | - Thomas Medsger
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
| | | | | | - Carla D'Aveta
- Rho Federal Systems Division, Durham, North Carolina
| | | | - R James White
- Division of Pulmonary and Critical Care Medicine, University of Rochester, Rochester, New York
| | - Paul M Hassoun
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Fernando Torres
- Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern, Dallas, Texas
| | - Andrew J Sweatt
- Division of Pulmonary, Allergy, and Critical Care Medicine and.,Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford, California
| | - Jerry A Molitor
- Division of Rheumatic and Autoimmune Diseases, University of Minnesota, Minneapolis, Minnesota
| | - Dinesh Khanna
- Division of Rheumatology, University of Michigan, Ann Arbor, Michigan
| | - Holden Maecker
- Division of Pulmonary, Allergy, and Critical Care Medicine and
| | - Beverly Welch
- National Institute of Allergy and Infectious Diseases, Bethesda, Maryland; and
| | - Ellen Goldmuntz
- National Institute of Allergy and Infectious Diseases, Bethesda, Maryland; and
| | - Mark R Nicolls
- Division of Pulmonary, Allergy, and Critical Care Medicine and.,Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford, California.,Veterans Affairs Palo Alto Health Care System, Palo Alto, California
| |
Collapse
|
22
|
Chung L, Spino C, McLain R, Johnson SR, Denton CP, Molitor JA, Steen VD, Lafyatis R, Simms RW, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Sandorfi N, Hant FN, Bernstein EJ, Chatterjee S, Castelino FV, Ajam A, Allanore Y, Matucci-Cerinic M, Whitfield ML, Distler O, Singer O, Young A, Nagaraja V, Fox DA, Furst DE, Khanna D. Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. Lancet Rheumatol 2020; 2:e743-e753. [PMID: 34966900 PMCID: PMC8713509 DOI: 10.1016/s2665-9913(20)30237-x] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND Abatacept was well tolerated by patients with early diffuse cutaneous systemic sclerosis in a phase 2, double-blind randomised trial, with potential efficacy at 12 months. We report here the results of an open-label extension for 6 months. METHODS Patients (aged ≥18 years) with diffuse cutaneous systemic sclerosis of less than 3 years' duration from their first non-Raynaud's symptom were enrolled into the ASSET trial (A Study of Subcutaneous Abatacept to Treat DiffuseCutaneous Systemic Sclerosis), which is a double-blind trial at 22 sites in Canada, the UK, and the USA. Aftercompletion of 12 months of treatment with either abatacept or placebo, patients received a further 6 months ofabatacept (125 mg subcutaneous every week) in an open-label extension. The primary endpoint of the double-blind trial was modified Rodnan Skin Score (mRSS) at 12 months, which was reassessed at 18 months in the open-label extension. The primary analysis included all participants who completed the double-blind trial and received at least one dose of open-label treatment (modified intention to treat). This trial is registered with ClinicalTrials.gov, NCT02161406. FINDINGS Between Sept 22, 2014, and March 15, 2017, 88 participants were randomly allocated in the double-blind trial either abatacept (n=44) or placebo (44); 32 patients from each treatment group completed the 6-month open-labelextension. Among patients assigned abatacept, a mean improvement from baseline in mRSS was noted at 12 months (-6·6 [SD 6·4]), with further improvement seen during the open-label extension period (-9·8 [8·1] at month 18). Participants assigned placebo had a mean improvement from baseline in mRSS at 12 months (-3·7 [SD 7·6]), with a further improvement at month 18 (-6·3 [9·3]). Infections during the open-label extension phase occurred in nine patients in the placebo-abatacept group (12 adverse events, one serious adverse event) and in 11 patients in theabatacept-abatacept group (14 adverse events, one serious adverse event). Two deaths occurred during the 12-month double-blind period in the abatacept group, which were related to scleroderma renal crisis; no deaths were recorded during the open-label extension. INTERPRETATION During the 6-month open-label extension, no new safety signals for abatacept were identified in the treatment of diffuse cutaneous systemic sclerosis. Clinically meaningful improvements in mRSS and other outcome measures were observed in both the abatacept and placebo groups when patients transitioned to open-label treatment. These data support further studies of abatacept in diffuse cutaneous systemic sclerosis. FUNDING Bristol-Myers Squibb and National Institutes of Health.
Collapse
Affiliation(s)
- Lorinda Chung
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Cathie Spino
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Richard McLain
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Sindhu R Johnson
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Christopher P Denton
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Jerry A Molitor
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Virginia D Steen
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Robert Lafyatis
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Robert W Simms
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Suzanne Kafaja
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Tracy M Frech
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Vivien Hsu
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Robyn T Domsic
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Janet E Pope
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Jessica K Gordon
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Maureen D Mayes
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Nora Sandorfi
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Faye N Hant
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Elana J Bernstein
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Soumya Chatterjee
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Flavia V Castelino
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Ali Ajam
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Yannick Allanore
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Marco Matucci-Cerinic
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Michael L Whitfield
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Oliver Distler
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Ora Singer
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Amber Young
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Vivek Nagaraja
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - David A Fox
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Daniel E Furst
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| | - Dinesh Khanna
- Stanford University School of Medicine, Stanford, CA, USA (Prof L Chung MD); Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA (Prof C Spino ScD, R McLain MS); Division of Rheumatology, Mount Sinai Hospital and University Health Network, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada (S R Johnson MD); University College London, Division of Medicine, London, UK (Prof C P Denton MD); Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA (J A Molitor MD); Rheumatology, Georgetown University Medical Center, Washington, DC, USA (ProfV D Steen MD); Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, USA (Prof R Lafyatis MD); Rheumatology, Boston University School of Medicine, Boston, MA, USA (Prof R W Simms MD); Rheumatology, Geisel School of Medicine, Dartmouth, Lebanon, NH, USA (Prof R W Simms); Department of Internal Medicine, University of Californiaat Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, USA (S Kafaja MD, Prof D E Furst MD); Division of Rheumatology, University of Utah, Salt Lake City, UT, USA (T M Frech MD); Rutgers-Robert Wood Johnson Medical School, Department of Medicine, Rheumatology Division, New Brunswick, NJ, USA (VHsu MD); Medicine-Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA (R T Domsic MD); Department of Medicine, University of Western Ontario, London, ON, Canada (Prof J E Pope MD); Rheumatology, Hospital for Special Surgery, NewYork, NY, USA (J K Gordon MD); McGovern Medical School, University of Texas, Houston, TX, USA (Prof MD Mayes MD); Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, USA (N Sandorfi MD); Medicine-Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA (F N Hant DO); Rheumatology, Columbia University, New York, NY, USA (E J Bernstein MD); Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA (S Chatterjee MD); Rheumatology, Harvard Medical School, Boston, MA, USA (F V Castelino MD); Division of Rheumatology-Immunology, Ohio State University Wexner Medical Center, Columbus, OH, USA (A Ajam MBBS); Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U1016, Université Sorbonne Paris Cité, and Cochin Hospital, Paris, France (Prof Y Allanore MD); Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology Azienda Ospedaliero Universitaria Careggi, Florence, Italy (Prof M Matucci-Cerinic MD); Geisel School of Medicine at Dartmouth, Hanover, NH, USA (Prof M L Whitfield PhD); Department of Rheumatology, University Hospital, Zurich, Switzerland (Prof O Distler MD); and Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA (O Singer MD, A Young MD, V Nagaraja MD, Prof D A Fox MD, Prof D Khanna MD)
| |
Collapse
|
23
|
Bernstein EJ, Jaafar S, Assassi S, Domsic RT, Frech TM, Gordon JK, Broderick RJ, Hant FN, Hinchcliff ME, Shah AA, Shanmugam VK, Steen VD, Khanna D. Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol 2020; 72:1892-1896. [PMID: 32583956 DOI: 10.1002/art.41415] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2019] [Accepted: 06/16/2020] [Indexed: 11/10/2022]
Abstract
OBJECTIVE Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Although pulmonary function tests (PFTs) are commonly used to screen for ILD in patients with SSc, studies have shown that they lack sensitivity for the detection of ILD in general SSc cohorts. This study was undertaken to assess the performance characteristics of PFTs for the detection of ILD in patients with early diffuse cutaneous SSc (dcSSc), a population at high risk for the development of ILD. METHODS We performed a retrospective cohort study of patients enrolled in the Prospective Registry of Early Systemic Sclerosis at 11 sites in the US between April 2012 and January 2019. Patients were included if they underwent spirometry and high-resolution computed tomography (HRCT) of the chest. We calculated the performance characteristics of PFTs for the detection of ILD on HRCT. RESULTS The study included 212 patients, 54% of whom had radiographic ILD. For the detection of ILD on HRCT imaging, a forced vital capacity (FVC) <80% predicted had a sensitivity of 63%. The combination of FVC <80% predicted or diffusing capacity for carbon monoxide (DLco) <80% predicted improved the sensitivity to 85%. An FVC <80% predicted had a negative predictive value (NPV) of 61%, while the combination of FVC <80% predicted or DLco <80% predicted had an NPV of 70%. CONCLUSION PFTs alone are an inadequate screening tool for the diagnosis of ILD in patients with early dcSSc. HRCT should be part of the ILD screening algorithm in patients with dcSSc.
Collapse
Affiliation(s)
| | | | | | - Robyn T Domsic
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| | | | | | | | - Faye N Hant
- Medical University of South Carolina, Charleston
| | | | - Ami A Shah
- Johns Hopkins University, Baltimore, Maryland
| | | | | | | |
Collapse
|
24
|
Hughes M, Pauling JD, Jones J, Denton CP, Domsic RT, Frech TM, Herrick AL, Khanna D, Matucci‐Cerinic M, McKenzie L, Saketkoo LA, Gooberman‐Hill R, Moore A. Multicenter Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis. Arthritis Care Res (Hoboken) 2020; 72:723-733. [DOI: 10.1002/acr.24127] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Accepted: 12/10/2019] [Indexed: 12/24/2022]
Affiliation(s)
- Michael Hughes
- University of Manchester, Manchester, Royal Hallamshire Hospital, and Sheffield Teaching Hospitals NHS Foundation Trust Sheffield UK
| | - John D. Pauling
- Royal National Hospital for Rheumatic Diseases and University of Bath Bath UK
| | | | | | | | - Tracy M. Frech
- University of Utah and Salt Lake Veterans Affairs Medical Center Salt Lake City
| | - Ariane L. Herrick
- University of ManchesterSalford Royal NHS Foundation Trust, and Manchester Academic Health Science Centre Manchester UK
| | | | | | - Lorraine McKenzie
- Patient representative (contact via Dr. Herrick, University of Manchester, Manchester, UK)
| | - Lesley Ann Saketkoo
- Tulane University School of MedicineNew Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, and University Medical Center Comprehensive Pulmonary Hypertension Center New Orleans Louisiana
| | - Rachael Gooberman‐Hill
- Bristol Medical School, NIHR Bristol Biomedical Research Centre, and University Hospitals Bristol NHS Foundation Trust Bristol UK
| | | |
Collapse
|
25
|
Pauling JD, Smith T, Domsic RT, Frech TM. Treatment efficacy in secondary Raynaud's phenomenon. Lancet Rheumatol 2020; 2:e132. [PMID: 38263651 DOI: 10.1016/s2665-9913(20)30030-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/31/2019] [Accepted: 01/28/2020] [Indexed: 01/25/2024]
Affiliation(s)
- John D Pauling
- Royal National Hospital for Rheumatic Diseases (part of Royal United Hospitals Bath NHS Foundation Trust), Bath BA1 3NG, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK.
| | - Theresa Smith
- Department of Mathematical Sciences, University of Bath, Bath, UK
| | - Robyn T Domsic
- University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - Tracy M Frech
- University of Utah and Salt Lake Regional Veterans Affair Medical Center, Salt Lake City, UT, USA
| |
Collapse
|
26
|
Hughes M, Pauling JD, Jones J, Denton CP, Domsic RT, Frech TM, Herrick AL, Khanna D, Matucci-Cerinic M, McKenzie L, Saketkoo LA, Gooberman-Hill R, Moore A. Patient experiences of digital ulcer development and evolution in systemic sclerosis. Rheumatology (Oxford) 2020; 59:2156-2158. [DOI: 10.1093/rheumatology/keaa037] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Accepted: 01/13/2020] [Indexed: 11/13/2022] Open
Affiliation(s)
- Michael Hughes
- Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
- Department of Rheumatology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
| | - John D Pauling
- Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Bath, UK
- Department of Pharmacy and Pharmacology, University of Bath, Bath, UK
| | - Jennifer Jones
- Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, Bristol, UK
| | - Christopher P Denton
- Department of Rheumatology, Royal Free Hospital, University College London, London, UK
| | - Robyn T Domsic
- Department of Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA
| | - Tracy M Frech
- Department of Rheumatology, University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, USA
| | - Ariane L Herrick
- Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
- Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Manchester, UK
| | - Dinesh Khanna
- Scleroderma Program, University of Michigan, Ann Arbor, MI, USA
| | | | - Lorraine McKenzie
- Patient representative, Contact via Professor Herrick, The University of Manchester, Manchester, UK
| | - Lesley Ann Saketkoo
- Tulane University School of Medicine, New Orleans Scleroderma & Sarcoidosis Patient Care & Research Center, UMC Comprehensive Pulmonary Hypertension Center, New Orleans, LA, USA
| | - Rachael Gooberman-Hill
- Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, Bristol, UK
- NIHR Bristol Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
| | - Andrew Moore
- Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, Bristol, UK
| |
Collapse
|
27
|
Khanna D, Spino C, Johnson S, Chung L, Whitfield M, Denton CP, Berrocal V, Jennifer F, Mehta B, Molitor J, Steen VD, Lafyatis R, Simms RW, Gill A, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Schiopu E, Young A, Sandorfi N, Park J, Hant FN, Bernstein EJ, Chatterjee S, Castelino FV, Ajam A, Wang Y, Wood T, Allanore Y, Matucci-Cerinic M, Distler O, Singer O, Bush E, Fox D, Furst DE. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis Rheumatol 2020; 72:125-136. [PMID: 31342624 PMCID: PMC6935399 DOI: 10.1002/art.41055] [Citation(s) in RCA: 143] [Impact Index Per Article: 35.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2019] [Accepted: 07/18/2019] [Indexed: 12/14/2022]
Abstract
OBJECTIVE T cells play a key role in the pathogenesis of early systemic sclerosis. This study was undertaken to assess the safety and efficacy of abatacept in patients with diffuse cutaneous systemic sclerosis (dcSSc). METHODS In this 12-month, randomized, double-blind, placebo-controlled trial, participants were randomized 1:1 to receive either subcutaneous abatacept 125 mg or matching placebo, stratified by duration of dcSSc. Escape therapy was allowed at 6 months for worsening disease. The coprimary end points were change in the modified Rodnan skin thickness score (MRSS) compared to baseline and safety over 12 months. Differences in longitudinal outcomes were assessed according to treatment using linear mixed models, with outcomes censored after initiation of escape therapy. Skin tissue obtained from participants at baseline was classified into intrinsic gene expression subsets. RESULTS Among 88 participants, the adjusted mean change in the MRSS at 12 months was -6.24 units for those receiving abatacept and -4.49 units for those receiving placebo, with an adjusted mean treatment difference of -1.75 units (P = 0.28). Outcomes for 2 secondary measures (Health Assessment Questionnaire disability index and a composite measure) were clinically and statistically significantly better with abatacept. The proportion of subjects in whom escape therapy was needed was higher in the placebo group relative to the abatacept group (36% versus 16%). In the inflammatory and normal-like skin gene expression subsets, decline in the MRSS over 12 months was clinically and significantly greater in the abatacept group versus the placebo group (P < 0.001 and P = 0.03, respectively). In the abatacept group, adverse events occurred in 35 participants versus 40 participants in the placebo group, including 2 deaths and 1 death, respectively. CONCLUSION In this phase II trial, abatacept was well-tolerated, but change in the MRSS was not statistically significant. Secondary outcome measures, including gene expression subsets, showed evidence in support of abatacept. These data should be confirmed in a phase III trial.
Collapse
Affiliation(s)
- Dinesh Khanna
- Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI
| | - Cathie Spino
- Biostatistics, University of Michigan, Ann Arbor, MI
| | - Sindhu Johnson
- Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada
| | - Lorinda Chung
- Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA
| | - Michael Whitfield
- Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover
| | | | | | - Franks Jennifer
- Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover
| | - Bhaven Mehta
- Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover
| | - Jerry Molitor
- Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN
| | - Virginia D. Steen
- Rheumatology, MedStar Georgetown University Hospital, Washington, DC
| | - Robert Lafyatis
- Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA
| | - Robert W. Simms
- Rheumatology, Boston University School of Medicine, Boston, MA
| | - Anna Gill
- UCL Division of Medicine, Royal Free Campus, London, United Kingdom
| | - Suzanne Kafaja
- Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA
| | - Tracy M. Frech
- Division of Rheumatology, University of Utah, Salt Lake City, UT
| | - Vivien Hsu
- Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ
| | - Robyn T. Domsic
- Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
| | - Janet E. Pope
- Department of Medicine, University of Western Ontario, London, ON, Canada
| | | | - Maureen D. Mayes
- Rheumatology, University of Texas McGovern Medical School, Houston, TX
| | - Elena Schiopu
- Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI
| | - Amber Young
- Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI
| | - Nora Sandorfi
- Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA
| | - Jane Park
- Seattle Rheumatology Associates, Seattle, WA
| | - Faye N. Hant
- Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC
| | | | | | | | - Ali Ajam
- Division of Rheumatology-Immunology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - Yue Wang
- Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover
| | - Tammara Wood
- Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover
| | | | - Marco Matucci-Cerinic
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Oliver Distler
- Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
| | - Ora Singer
- Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI
| | - Erica Bush
- Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI
| | - David Fox
- Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI
| | | |
Collapse
|
28
|
Saygin D, Domsic RT. Pulmonary Arterial Hypertension In Systemic Sclerosis: Challenges In Diagnosis, Screening And Treatment. Open Access Rheumatol 2019; 11:323-333. [PMID: 31920409 PMCID: PMC6939800 DOI: 10.2147/oarrr.s228234] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2019] [Accepted: 10/15/2019] [Indexed: 12/31/2022] Open
Abstract
Systemic sclerosis (SSc) is a chronic, multisystem autoimmune disease characterized by vasculopathy, fibrosis and immune system activation. Pulmonary hypertension and interstitial lung disease account for majority of SSc-related deaths. Diagnosis of SSc-PAH can be challenging due to nonspecific clinical presentation which can lead to delayed diagnosis. Many screening algorithms have been developed to detect SSc-associated pulmonary arterial hypertension (SSc-PAH) in early stages. Currently used PAH-specific medications are largely extrapolated from IPAH studies due to smaller number of patients with SSc-PAH. In this review, we discuss the current state of knowledge in epidemiology and risk factors for development of SSc-PAH, and challenges and potential solutions in the diagnosis, screening and management of SSc-PAH.
Collapse
Affiliation(s)
- Didem Saygin
- Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - Robyn T Domsic
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| |
Collapse
|
29
|
Skaug B, Khanna D, Swindell WR, Hinchcliff ME, Frech TM, Steen VD, Hant FN, Gordon JK, Shah AA, Zhu L, Zheng WJ, Browning JL, Barron AMS, Wu M, Visvanathan S, Baum P, Franks JM, Whitfield ML, Shanmugam VK, Domsic RT, Castelino FV, Bernstein EJ, Wareing N, Lyons MA, Ying J, Charles J, Mayes MD, Assassi S. Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Ann Rheum Dis 2019; 79:379-386. [PMID: 31767698 DOI: 10.1136/annrheumdis-2019-215894] [Citation(s) in RCA: 85] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2019] [Revised: 11/07/2019] [Accepted: 11/07/2019] [Indexed: 01/01/2023]
Abstract
OBJECTIVES Determine global skin transcriptome patterns of early diffuse systemic sclerosis (SSc) and how they differ from later disease. METHODS Skin biopsy RNA from 48 patients in the Prospective Registry for Early Systemic Sclerosis (PRESS) cohort (mean disease duration 1.3 years) and 33 matched healthy controls was examined by next-generation RNA sequencing. Data were analysed for cell type-specific signatures and compared with similarly obtained data from 55 previously biopsied patients in Genetics versus Environment in Scleroderma Outcomes Study cohort with longer disease duration (mean 7.4 years) and their matched controls. Correlations with histological features and clinical course were also evaluated. RESULTS SSc patients in PRESS had a high prevalence of M2 (96%) and M1 (94%) macrophage and CD8 T cell (65%), CD4 T cell (60%) and B cell (69%) signatures. Immunohistochemical staining of immune cell markers correlated with the gene expression-based immune cell signatures. The prevalence of immune cell signatures in early diffuse SSc patients was higher than in patients with longer disease duration. In the multivariable model, adaptive immune cell signatures were significantly associated with shorter disease duration, while fibroblast and macrophage cell type signatures were associated with higher modified Rodnan Skin Score (mRSS). Immune cell signatures also correlated with skin thickness progression rate prior to biopsy, but did not predict subsequent mRSS progression. CONCLUSIONS Skin in early diffuse SSc has prominent innate and adaptive immune cell signatures. As a prominently affected end organ, these signatures reflect the preceding rate of disease progression. These findings could have implications in understanding SSc pathogenesis and clinical trial design.
Collapse
Affiliation(s)
- Brian Skaug
- Division of Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Dinesh Khanna
- Scleroderma Program, Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA
| | - William R Swindell
- Ohio University Heritage College of Osteopathic Medicine, Athens, Ohio, USA.,Department of Internal Medicine, The Jewish Hospital, Cincinnati, Ohio, USA
| | - Monique E Hinchcliff
- Department of Medicine, Section of Allergy, Rheumatology, and Immunology, Yale University, New Haven, Connecticut, USA
| | - Tracy M Frech
- Division of Rheumatology, Department of Internal Medicine, University of Utah and Salt Lake Regional Veterans Affairs Medical Center, Salt Lake City, Utah, USA
| | - Virginia D Steen
- Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, USA
| | - Faye N Hant
- Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Jessica K Gordon
- Department of Rheumatology, Hospital for Special Surgery, New York City, New York, USA
| | - Ami A Shah
- Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Lisha Zhu
- School of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - W Jim Zheng
- School of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Jeffrey L Browning
- Department of Microbiology, Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA
| | - Alexander M S Barron
- Department of Microbiology, Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA
| | - Minghua Wu
- Division of Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Sudha Visvanathan
- Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA
| | - Patrick Baum
- Boehringer Ingelheim International GmbH, Biberach, Germany
| | - Jennifer M Franks
- Department of Biomedical Data Science, Dartmouth College Geisel School of Medicine, Lebanon, New Hampshire, USA.,Department of Molecular and Systems Biology, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire, USA
| | - Michael L Whitfield
- Department of Biomedical Data Science, Dartmouth College Geisel School of Medicine, Lebanon, New Hampshire, USA.,Department of Molecular and Systems Biology, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire, USA
| | - Victoria K Shanmugam
- Division of Rheumatology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
| | - Robyn T Domsic
- Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Flavia V Castelino
- Division of Rheumatology, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Elana J Bernstein
- Division of Rheumatology, Vagelos College of Physicians and Surgeons, New York City, New York, USA
| | - Nancy Wareing
- Division of Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Marka A Lyons
- Division of Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Jun Ying
- Division of Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Julio Charles
- Division of Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Maureen D Mayes
- Division of Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Shervin Assassi
- Division of Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA
| |
Collapse
|
30
|
Nagaraja V, Spino C, Bush E, Tsou PS, Domsic RT, Lafyatis R, Frech T, Gordon JK, Steen VD, Khanna D. A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. Arthritis Res Ther 2019; 21:202. [PMID: 31481106 PMCID: PMC6724329 DOI: 10.1186/s13075-019-1979-7] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2019] [Accepted: 08/16/2019] [Indexed: 11/10/2022] Open
Abstract
Background To determine the effect of riociguat, an oral, selective soluble guanylate cyclase stimulator, on the net digital ulcer (DU) burden in systemic sclerosis (SSc). Methods Participants with SSc-related active or painful indeterminate DUs were recruited in a multicenter, double-blind, randomized, placebo-controlled, proof-of-concept trial. Eligible participants were required to have at least one visible, active ischemic DU or painful indeterminate DU at screening, located at or distal to the proximal interphalangeal joint and that developed or worsened within 8 weeks prior to screening. Participants were randomized 1:1 to placebo or riociguat in individualized doses (maximum of 2.5 mg three times daily) during an 8-week titration period, followed by an 8-week stable dosing period. This was followed by an optional 16-week open-label extension phase for participants with active DU/reoccurrence of DUs within 1 month of the end of the main treatment phase. The primary endpoint was the change from baseline to week 16 in net ulcer burden (NUB), analyzed using ANCOVA. Other endpoints included plasma biomarkers and proportion of participants with treatment-emergent adverse events (AEs). Results Seventeen participants (eight placebo, nine riociguat) were randomized at five centers. Six participants in each group transitioned to the open-label extension. Baseline characteristics were comparable between the treatment groups, except participants randomized to placebo were older and had longer disease duration (p < 0.05). At baseline, the mean (SD) NUB was 2.5 (2.0) in the placebo and 2.4 (1.4) in the riociguat. No significant treatment difference was observed in the change from baseline to 16 weeks in NUB (adjusted mean treatment difference − 0.24, 95% CI (− 1.46, 0.99), p = 0.70). Four participants experienced five serious AE (four in riociguat and one in placebo); none was considered related to study medication. Statistically significant elevation of cGMP was observed at 16 weeks in the riociguat group (p = 0.05); no other biomarkers showed significant changes. In the open-label extension, participants in the riociguat-riociguat arm had complete healing of their DUs. Conclusion In participants with SSc-DU, treatment with riociguat did not reduce the number of DU net burden compared with placebo at 16 weeks. Open-label extension suggests that longer duration is needed to promote DU healing, which needs to be confirmed in a new trial. Trial registration ClinicalTrials.gov, NCT02915835. Registered on September 27, 2016. Electronic supplementary material The online version of this article (10.1186/s13075-019-1979-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Vivek Nagaraja
- Division of Rheumatology/Department of Internal Medicine, University of Michigan Scleroderma Program, Suite 7C27, 300 North Ingalls Street, SPC 5422, Ann Arbor, MI, 48109, USA
| | - Cathie Spino
- Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA
| | - Erica Bush
- Division of Rheumatology/Department of Internal Medicine, University of Michigan Scleroderma Program, Suite 7C27, 300 North Ingalls Street, SPC 5422, Ann Arbor, MI, 48109, USA
| | - Pei-Suen Tsou
- Division of Rheumatology/Department of Internal Medicine, University of Michigan Scleroderma Program, Suite 7C27, 300 North Ingalls Street, SPC 5422, Ann Arbor, MI, 48109, USA
| | - Robyn T Domsic
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - Robert Lafyatis
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - Tracy Frech
- Division of Rheumatology, University of Utah, Salt Lake City, UT, USA
| | - Jessica K Gordon
- Division of Rheumatology, Hospital of Special Surgery, New York, NY, USA
| | - Virginia D Steen
- Division of Rheumatology, Georgetown University Medical Center, Washington, DC, USA
| | - Dinesh Khanna
- Division of Rheumatology/Department of Internal Medicine, University of Michigan Scleroderma Program, Suite 7C27, 300 North Ingalls Street, SPC 5422, Ann Arbor, MI, 48109, USA.
| |
Collapse
|
31
|
McMahan ZH, Domsic RT, Zhu L, Medsger TA, Casciola-Rosen L, Shah AA. Anti-RNPC-3 (U11/U12) Antibodies in Systemic Sclerosis in Patients With Moderate-to-Severe Gastrointestinal Dysmotility. Arthritis Care Res (Hoboken) 2019; 71:1164-1170. [PMID: 30242973 PMCID: PMC6430701 DOI: 10.1002/acr.23763] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Accepted: 09/18/2018] [Indexed: 12/25/2022]
Abstract
OBJECTIVE To examine the association of anti-RNPC-3 antibodies in patients with systemic sclerosis (scleroderma or SSc) with selected gastrointestinal (GI) tract complications. METHODS Sera from patients with SSc with or without severe GI dysfunction (total parenteral nutrition dependence) from the Johns Hopkins Scleroderma Center were screened for anti-RNPC-3 antibodies. We then examined anti-RNPC-3-positive cases and negative SSc controls from the University of Pittsburgh and the University of Pittsburgh Medical Center (UPMC) scleroderma cohort to confirm our findings and to examine whether specific GI features were associated with anti-RNPC-3 antibodies. RESULTS In the discovery cohort, patients with SSc with severe GI dysfunction (n = 37) and without GI dysfunction (n = 38) were screened for anti-RNPC-3 antibodies. The former were more likely to have anti-RNPC-3 antibodies (14% versus 3%; P = 0.11). In the Pittsburgh cohort, moderate-to-severe GI dysfunction (Medsger GI score ≥2) was present in 36% of anti-RNPC-3-positive patients versus 15% of anti-RNPC-3-negative patients (P ≤ 0.01). Anti-RNPC-3-positive patients were more likely to be male (31% versus 15%; P = 0.04), African American (18% versus 6%; P = 0.02), have esophageal dysmotility (93% versus 62%; P < 0.01), and interstitial lung disease (ILD) (77% versus 35%; P < 0.01). After adjusting for relevant covariates and potential confounders, moderate-to-severe GI disease was associated with anti-RNPC-3 antibodies (odds ratio [OR] 3.8 [95% confidence interval (95% CI) 1.0-14.3]), and ILD trended toward significance (OR 2.8 [95% CI 1.0-8.2]). CONCLUSION Patients with SSc and anti-RNPC-3 antibodies are more likely to be male and African American and to have moderate-to-severe GI disease and ILD. Further studies on larger patient cohorts may be helpful in further defining subsets of patients with SSc at risk for severe GI involvement.
Collapse
Affiliation(s)
| | - Robyn T Domsic
- University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
| | - Lei Zhu
- University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
| | - Thomas A Medsger
- University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
| | | | - Ami A Shah
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| |
Collapse
|
32
|
Shah DJ, Hirpara R, Poelman CL, Woods A, Hummers LK, Wigley FM, Wright JL, Parekh A, Steen VD, Domsic RT, Shah AA. Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients With Breast Cancer. Arthritis Care Res (Hoboken) 2019; 70:1517-1524. [PMID: 29316366 DOI: 10.1002/acr.23505] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Accepted: 01/02/2018] [Indexed: 11/10/2022]
Abstract
OBJECTIVE We examined systemic sclerosis (SSc) patients with breast cancer to identify the prevalence of radiation complications and to examine outcomes in SSc patients who received radiation therapy as part of their cancer treatment. METHODS Patients with SSc and breast cancer were identified from the Johns Hopkins and University of Pittsburgh Scleroderma Center databases. We examined whether erythema, blistering, ulceration, or thickening of the skin developed in the radiation therapy port. Changes in modified Rodnan skin thickness score (mRSS) and forced vital capacity percent predicted (FVC%) at 12 and 24 months post-cancer diagnosis were compared between patients who did and those who did not receive radiation therapy. RESULTS A total of 43 of 116 breast cancer patients at Johns Hopkins and 26 of 37 patients at the University of Pittsburgh received breast radiation therapy. At Johns Hopkins, 4 of 30 (13.3%) patients with available data developed erythema, none had blistering, 1 of 30 (3.3%) developed ulceration, and 15 of 31 (48.4%) had skin thickening in the radiation port. At the University of Pittsburgh, 7 of 11 patients (63.6%) with available data developed erythema, 2 of 11 (18.2%) had blistering, none developed ulceration, and 6 of 11 (54.6%) had skin thickening in the radiation port. In a limited sample, there were no significant changes in the mRSS or FVC% between patients who did and those who did not receive radiation therapy. CONCLUSION These data suggest that radiation injury causing local tissue fibrosis is not inevitable in SSc patients with breast cancer, occurring in approximately 50% of patients without evidence of lung or generalized skin disease flare. Therefore, the use of radiation therapy for breast cancer is considered an option based on the informed patient's preference.
Collapse
Affiliation(s)
- Dhaval J Shah
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Ram Hirpara
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Corrie L Poelman
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Adrianne Woods
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Laura K Hummers
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | | | - Jean L Wright
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Arti Parekh
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | | | | | - Ami A Shah
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| |
Collapse
|
33
|
Gupta S, Gupta A, Rehman S, Ocak I, Domsic RT, Schneider F, George MP. Pulmonary veno-occlusive disease is highly prevalent in scleroderma patients undergoing lung transplantation. ERJ Open Res 2019; 5:00168-2018. [PMID: 30775371 PMCID: PMC6368993 DOI: 10.1183/23120541.00168-2018] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2018] [Accepted: 12/10/2018] [Indexed: 11/25/2022] Open
Abstract
Pulmonary complications including pulmonary hypertension (PH) and interstitial lung disease (ILD) are leading causes of mortality in systemic sclerosis/scleroderma (SSc) [1]. PH associated with SSc (SSc-PH) has been attributed to World Health Organization (WHO) group 1 disease, pulmonary arterial hypertension (SSc-PAH); WHO group 2 due to left ventricular systolic or diastolic dysfunction (SSc-PVH); or WHO group 3 related to interstitial lung disease (SSc-PH-ILD) [2, 3]. SSc-PH is found in 10–12% of SSc patients [4]. Of the 71 out of 237 patients in the PHAROS (Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma) cohort who had PH, 69% had SSc-PAH, 10% had SSc-PVH and 21% had SSc-PH-ILD [1]. SSc-PAH has poor prognosis and less favourable response to pulmonary vasodilator therapy compared to idiopathic pulmonary arterial hypertension (IPAH) [5, 6]. SSc-PH-ILD is a strong predictor of death compared to SSc-PAH or ILD alone [7]. There is an unexpectedly high incidence of PVOD in patients with SSc-PH-ILD. Presence of PVOD may be an unrecognised contributor to the dismal prognosis of these patients. Early transplant referral should be considered for those with SSc-PH-ILD.http://ow.ly/vPvc30neJZV
Collapse
Affiliation(s)
- Shikha Gupta
- Division of Pulmonary, Allergy and Critical Care Medicine, Dept of Medicine, UPMC, Pittsburgh, PA, USA
| | - Aman Gupta
- Dept of General Internal Medicine, UPMC, Pittsburgh, PA, USA
| | - Sofiya Rehman
- Dept of Internal Medicine, UPMC, Mckeesport, PA, USA
| | - Iclal Ocak
- Thoracic Imaging Division, Dept of Radiology, UPMC, Pittsburgh, PA, USA
| | - Robyn T Domsic
- Division of Rheumatology and Clinical Immunology, Dept of Medicine, UPMC, Pittsburgh, PA, USA
| | | | - M Patricia George
- Division of Pulmonary Medicine, Dept of Medicine, National Jewish Health, Denver, CO, USA
| |
Collapse
|
34
|
Hsu VM, Chung L, Hummers LK, Shah A, Simms R, Bolster M, Hant FN, Silver RM, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Saketkoo LA, Salazar CR, Steen VD. Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. J Rheumatol 2018; 46:176-183. [PMID: 30275260 DOI: 10.3899/jrheum.180018] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/18/2018] [Indexed: 12/22/2022]
Abstract
OBJECTIVE We sought to identify predictors of mortality and cardiopulmonary hospitalizations in patients at risk for pulmonary hypertension (PH) and enrolled in PHAROS, a prospective cohort study to investigate the natural history of PH in systemic sclerosis (SSc). METHODS The at-risk population for PH was defined by the following entry criteria: echocardiogram systolic pulmonary arterial pressure > 40 mmHg, or DLCO < 55% predicted or ratio of % forced vital capacity/%DLCO > 1.6, measured by pulmonary function testing. Baseline clinical measures were evaluated as predictors of hospitalization and death between 2005 and 2014. Cox proportional hazards models were censored at date of PH onset or latest study visit and adjusted for age, sex, race, and disease duration. RESULTS Of the 236 at-risk subjects who were followed for a median of 4 years (range 0.4-8.5 yrs), 35 developed PH after entering PHAROS (reclassified as PH group). In the at-risk group, higher mortality was strongly associated with male sex, low %DLCO, exercise oxygen desaturation, anemia, abnormal dyspnea scores, and baseline pericardial effusion. Risks for cardiopulmonary hospitalization were associated with increased dyspnea and pericardial effusions, although PH patients with DLCO < 50% had the highest risk of cardiopulmonary hospitalizations. CONCLUSION Risk factors for poor outcome in patients with SSc who are at risk for PH were similar to others with SSc-PH and SSc-pulmonary arterial hypertension, including male sex, DLCO < 50%, exercise oxygen desaturation, and pericardial effusions. This group should undergo right heart catheterization and receive appropriate intervention if PH is confirmed.
Collapse
Affiliation(s)
- Vivien M Hsu
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA. .,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University.
| | - Lorinda Chung
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Laura K Hummers
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Ami Shah
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Robert Simms
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Marcy Bolster
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Faye N Hant
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Richard M Silver
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Aryeh Fischer
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Monique E Hinchcliff
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - John Varga
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Avram Z Goldberg
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Chris T Derk
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Elena Schiopu
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Dinesh Khanna
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Lee S Shapiro
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Robyn T Domsic
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Thomas Medsger
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Maureen D Mayes
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Daniel Furst
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Mary Ellen Csuka
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Jerry A Molitor
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Lesley Ann Saketkoo
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Christian R Salazar
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| | - Virginia D Steen
- From the Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, California; Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Department of Medicine, Division of Rheumatology, Boston University, Boston; Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado; Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, Illinois; Department of Medicine, Division of Rheumatology, New York University Medical Center, New York, New York; Department of Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, Division of Rheumatology, University of Texas, Houston, Texas; Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California; Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Division of Rheumatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University, New Orleans, Louisiana; Department of Epidemiology and Health Promotion, New York University, New York, New York; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University, Washington, D.C., USA.,V.M. Hsu, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Rutgers-Robert Wood Johnson Medical School; L. Chung, MD, MS, Associate Professor of Medicine and Dermatology, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; L.K. Hummers, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; A. Shah, MD, Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Johns Hopkins University; R. Simms, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Boston University; M. Bolster, MD, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; F.N. Hant, DO, MSCR, Associate Professor, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; R.M. Silver, MD, Department of Medicine, Division of Rheumatology, Medical University of South Carolina; A. Fischer, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, and Pulmonary Sciences and Critical Care Medicine, University of Colorado; M.E. Hinchcliff, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, Northwestern University; J. Varga, MD, Professor of Medicine, Dermatology and Pharmacology, Department of Medicine, Division of Rheumatology, Northwestern University; A.Z. Goldberg, MD, Clinical Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, New York University Medical Center; C.T. Derk, MD, MS, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pennsylvania; E. Schiopu, MD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; D. Khanna, MD, MBBS, MSc, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Michigan; L.S. Shapiro, MD, Clinical Professor of Medicine, Department of Medicine, Division of Rheumatology, Albany Medical College; R.T. Domsic, MD, MPH, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; T. Medsger, MD, Gerald P. Rodnan Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Pittsburgh; M.D. Mayes, MD, MPH, Professor of Medicine, Rheumatology and Immunogenetics, Department of Medicine, Division of Rheumatology, University of Texas; D. Furst, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of California at Los Angeles; M.E. Csuka, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin; J.A. Molitor, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Minnesota; L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Department of Medicine, Divisions of Pulmonary and Rheumatology, Tulane University; C.R. Salazar, PhD, MPH, Adjunct Assistant Professor, Department of Epidemiology and Health Promotion, New York University; V.D. Steen, MD, Professor of Medicine, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Georgetown University
| |
Collapse
|
35
|
Gourh P, Remmers EF, Boyden SE, Alexander T, Morgan ND, Shah AA, Mayes MD, Doumatey A, Bentley AR, Shriner D, Domsic RT, Medsger TA, Steen VD, Ramos PS, Silver RM, Korman B, Varga J, Schiopu E, Khanna D, Hsu V, Gordon JK, Saketkoo LA, Gladue H, Kron B, Criswell LA, Derk CT, Bridges SL, Shanmugam VK, Kolstad KD, Chung L, Jan R, Bernstein EJ, Goldberg A, Trojanowski M, Kafaja S, Maksimowicz-McKinnon KM, Mullikin JC, Adeyemo A, Rotimi C, Boin F, Kastner DL, Wigley FM. Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans. Arthritis Rheumatol 2018; 70:1654-1660. [PMID: 29732714 DOI: 10.1002/art.40541] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Accepted: 04/26/2018] [Indexed: 01/11/2023]
Abstract
OBJECTIVE Whole-exome sequencing (WES) studies in systemic sclerosis (SSc) patients of European American (EA) ancestry have identified variants in the ATP8B4 gene and enrichment of variants in genes in the extracellular matrix (ECM)-related pathway that increase SSc susceptibility. This study was undertaken to evaluate the association of the ATP8B4 gene and the ECM-related pathway with SSc in a cohort of African American (AA) patients. METHODS SSc patients of AA ancestry were enrolled from 23 academic centers across the US under the Genome Research in African American Scleroderma Patients consortium. Unrelated AA individuals without serologic evidence of autoimmunity who were enrolled in the Howard University Family Study were used as unaffected controls. Functional variants in genes reported in the 2 WES studies in EA patients with SSc were selected for gene association testing using the optimized sequence kernel association test (SKAT-O) and pathway analysis by Ingenuity Pathway Analysis in 379 patients and 411 controls. RESULTS Principal components analysis demonstrated that the patients and controls had similar ancestral backgrounds, with roughly equal proportions of mean European admixture. Using SKAT-O, we examined the association of individual genes that were previously reported in EA patients and none remained significant, including ATP8B4 (P = 0.98). However, we confirmed the previously reported association of the ECM-related pathway with enrichment of variants within the COL13A1, COL18A1, COL22A1, COL4A3, COL4A4, COL5A2, PROK1, and SERPINE1 genes (corrected P = 1.95 × 10-4 ). CONCLUSION In the largest genetic study in AA patients with SSc to date, our findings corroborate the role of functional variants that aggregate in a fibrotic pathway and increase SSc susceptibility.
Collapse
Affiliation(s)
- Pravitt Gourh
- NIAMS and National Human Genome Research Institute, NIH, Bethesda, Maryland
| | - Elaine F Remmers
- National Human Genome Research Institute, NIH, Bethesda, Maryland
| | - Steven E Boyden
- National Human Genome Research Institute, NIH, Bethesda, Maryland
| | | | - Nadia D Morgan
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Ami A Shah
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | | | - Ayo Doumatey
- National Human Genome Research Institute, NIH, Bethesda, Maryland
| | - Amy R Bentley
- National Human Genome Research Institute, NIH, Bethesda, Maryland
| | - Daniel Shriner
- National Human Genome Research Institute, NIH, Bethesda, Maryland
| | | | | | | | | | | | - Benjamin Korman
- Northwestern University, Feinberg School of Medicine, Chicago, Illinois
| | - John Varga
- Northwestern University, Feinberg School of Medicine, Chicago, Illinois
| | | | | | - Vivien Hsu
- Robert Wood Johnson University, New Brunswick, New Jersey
| | | | | | - Heather Gladue
- Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, North Carolina
| | | | | | | | | | | | | | - Lorinda Chung
- Stanford University School of Medicine, Stanford, California, and Palo Alto VA Health Care System, Palo Alto, California
| | - Reem Jan
- University of Chicago, Pritzker School of Medicine, Chicago, Illinois
| | - Elana J Bernstein
- New York Presbyterian Hospital, Columbia University, New York, New York
| | - Avram Goldberg
- New York University Langone Medical Center, New York, New York
| | | | - Suzanne Kafaja
- David Geffen School of Medicine, University of California, Los Angeles
| | | | - James C Mullikin
- National Human Genome Research Institute, NIH Intramural Sequencing Center, Rockville, Maryland
| | | | - Charles Rotimi
- National Human Genome Research Institute, NIH, Bethesda, Maryland
| | | | - Daniel L Kastner
- National Human Genome Research Institute, NIH, Bethesda, Maryland
| | | |
Collapse
|
36
|
Pauling JD, Domsic RT, Saketkoo LA, Almeida C, Withey J, Jay H, Frech TM, Ingegnoli F, Dures E, Robson J, McHugh NJ, Herrick AL, Matucci-Cerinic M, Khanna D, Hewlett S. Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis. Arthritis Care Res (Hoboken) 2018; 70:1373-1384. [PMID: 29473715 DOI: 10.1002/acr.23475] [Citation(s) in RCA: 52] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2017] [Accepted: 11/14/2017] [Indexed: 11/07/2022]
Abstract
OBJECTIVE Raynaud's phenomenon (RP) is the most common manifestation of systemic sclerosis (SSc). RP is an episodic phenomenon, not easily assessed in the clinic, leading to reliance on self-report. A thorough understanding of the patient experience of SSc-RP is essential to ensuring that patient-reported outcome (PRO) instruments capture domains important to the target patient population. We report the findings of an international qualitative research study investigating the patient experience of SSc-RP. METHODS Focus groups of SSc patients were conducted across 3 scleroderma centers in the US and UK, using a topic guide and a priori purposive sampling framework devised by qualitative researchers, SSc patients, and SSc experts. Focus groups were audio recorded, transcribed, anonymized, and analyzed using inductive thematic analysis. Focus groups were conducted until thematic saturation was achieved. RESULTS Forty SSc patients participated in 6 focus groups conducted in Bath (UK), New Orleans (Louisiana), and Pittsburgh (Pennsylvania). Seven major themes were identified that encapsulate the patient experience of SSc-RP: physical symptoms, emotional impact, triggers and exacerbating factors, constant vigilance and self-management, impact on daily life, uncertainty, and adaptation. The interrelationship of the 7 constituent themes can be arranged within a conceptual map of SSc-RP. CONCLUSION We have explored the patient experience of SSc-RP in a diverse and representative SSc cohort and identified a complex interplay of experiences that result in significant impact. Work to develop a novel PRO instrument for assessing the severity and impact of SSc-RP, comprising domains/items grounded in the patient experiences of SSc-RP identified in this study, is underway.
Collapse
Affiliation(s)
- John D Pauling
- Royal National Hospital for Rheumatic Diseases (at Royal United Hospitals), and University of Bath, Bath, UK
| | - Robyn T Domsic
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| | | | | | - Jane Withey
- Royal National Hospital for Rheumatic Diseases (at Royal United Hospitals), Bath, UK
| | - Hilary Jay
- Royal National Hospital for Rheumatic Diseases (at Royal United Hospitals), Bath, UK
| | - Tracy M Frech
- University of Utah and Salt Lake Regional Veterans Affairs Medical Center, Salt Lake City
| | | | - Emma Dures
- University of the West of England, Bristol, UK
| | | | - Neil J McHugh
- Royal National Hospital for Rheumatic Diseases (at Royal United Hospitals), and University of Bath, Bath, UK
| | - Ariane L Herrick
- University of Manchester, Salford Royal Hospital NHS Foundation Trust, and Manchester Academic Health Science Centre, Manchester, UK
| | | | | | | |
Collapse
|
37
|
Baron M, Kahaleh B, Bernstein EJ, Chung L, Clements PJ, Denton C, Domsic RT, Ferdowsi N, Foeldvari I, Frech T, Gordon JK, Hudson M, Johnson SR, Khanna D, McMahan Z, Merkel PA, Narain S, Nikpour M, Pauling JD, Ross L, Valenzuela Vergara AM, Vacca A. An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups. J Scleroderma Relat Disord 2018; 4:17-27. [PMID: 30906878 DOI: 10.1177/2397198318783926] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The Scleroderma Clinical Trials Consortium (SCTC) represents many of the clinical researchers in the world who are interested in improving the efficiency of clinical trials in Systemic Sclerosis (SSc). The SCTC has established 11 working groups (WGs) to develop and validate better ways of measuring and recording multiple aspects of this heterogeneous disease. These include groups working on arthritis, disease damage, disease activity, cardiac disease, juvenile SSc, the gastrointestinal tract, vascular component, calcinosis, scleroderma renal crisis, interstitial lung disease, and skin measurement. Members of the SCTC may join any one or more of these groups. Some of the WGs have only recently started their work, some are nearing completion of their mandated tasks and others are in the midst of their projects. All these projects, which are described in this paper, will help to improve clinical trials and observational studies by improving or developing better, more sensitive ways of measuring various aspects of the disease. As Lord Kelvin stated, "To measure is to know. If you cannot measure it you cannot improve it." The SCTC is dedicated to improving the lives of patients with SSc and it is our hope that the contributions of the WGs will be one important step in this process.
Collapse
Affiliation(s)
- Murray Baron
- Division of Rheumatology, Jewish General Hospital, Montreal, Canada
| | - Bashar Kahaleh
- Faculty of Rheumatology, University of Toledo Medical Center, Toledo, OH, USA
| | - Elana J Bernstein
- Columbia University College of Physicians and Surgeons, New York, New York
| | - Lorinda Chung
- Department of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA
| | - Philip J Clements
- Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA; University College London, London, United Kingdom
| | - Christopher Denton
- Insitute of Immunity and Transplantation, University College London, London, United Kingdom
| | - Robyn T Domsic
- Arthritis and Autoimmunity Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - Nava Ferdowsi
- Division of Rheumatology, St. Vincent's Hospital, Melbourne, Australia
| | - Ivan Foeldvari
- Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany
| | - Tracy Frech
- Department of Rheumatology, University of Utah, UT, USA
| | - Jessica K Gordon
- Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA
| | - Marie Hudson
- Division of Rheumatology, Jewish General Hospital, Montreal, Canada
| | - Sindhu R Johnson
- Department of Rheumatology, Toronto Western Hospital, Toronto, Canada
| | - Dinesh Khanna
- Division of Rheumatology, University of Michigan, MI, USA
| | | | - Peter A Merkel
- Department of Medicine, University of Pennsylvania, PA, USA
| | - Sonali Narain
- Department of Rheumatology, Hosfra Northwell School of Medicine
| | - Mandana Nikpour
- Division of Rheumatology, St. Vincent's Hospital, Melbourne, Australia
| | - John D Pauling
- Department of Rheumatology, Royal National Hospital for Rheumatic Diseases University of Bath
| | - Laura Ross
- Division of Rheumatology, St. Vincent's Hospital, Melbourne, Australia
| | | | | |
Collapse
|
38
|
Pauling JD, Frech TM, Hughes M, Gordon JK, Domsic RT, Anderson ME, Ingegnoli F, McHugh NJ, Johnson SR, Hudson M, Boin F, Ong VH, Matucci-Cerinic M, Altorok N, Scolnik M, Nikpour M, Shah A, Pope JE, Khanna D, Herrick AL. Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report. J Scleroderma Relat Disord 2018; 3:249-252. [PMID: 30705970 DOI: 10.1177/2397198318774307] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The episodic nature of Raynaud's phenomenon (RP) in systemic sclerosis (SSc) has led to a reliance on patient-reported outcome (PRO) instruments such as the Raynaud's Condition Score (RCS) diary. Little is known about the utilisation in routine clinical practice and health professional attitudes towards existing PRO instruments for assessing SSc-RP. Members of the Scleroderma Clinical Trials Consortium Vascular Working Group (SCTC-VWG, n=28) were invited to participate in a survey gauging attitudes towards the RCS diary and the perceived need for novel PRO instruments for assessing SSc-RP. Nineteen SCTC-VWG members (68% response rate) from academic units based in North America (n=9), Europe (n=8), South America (n=1) and Australasia (n=1) took part in the survey. There was broad consensus that RCS diary returns could be influenced by factors including seasonal variation in weather, efforts made by patients to avoid or ameliorate attacks of RP, habituation to RP symptoms, evolution of RP symptom characteristics with progressive obliterative microangiopathy, patient coping strategies, respondent burden and placebo effect. There was consensus that limitations of the RCS diary might be a barrier to drug development (79% of respondents agree/strongly agree) and that a novel PRO instrument for assessing SSc-RP should be developed with the input of both clinicians and patients (84% agree/strongly agree). Perceived potential limitations of the RCS diary have been identified along with concerns that such factors might impede drug development programs for SSc-RP. There is support within the systemic sclerosis community for the development of a novel PRO instrument for assessing SSc-RP.
Collapse
Affiliation(s)
- John D Pauling
- Royal National Hospital for Rheumatic Diseases (at Royal United Hospitals), Bath, UK.,Department of Pharmacy and Pharmacology, University of Bath, Bath, UK
| | - Tracy M Frech
- University of Utah and Salt Lake Regional Veterans Affair Medical Center, Salt Lake City, UT
| | - Michael Hughes
- Centre for Musculoskeletal Research, The University of Manchester, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester
| | | | | | - Marina E Anderson
- Institute of Ageing and Chronic Disease, Faculty of Health and Life Sciences, University of Liverpool & Aintree University Hospital
| | - Francesca Ingegnoli
- Division of Rheumatology, Dept. of Clinical Sciences and Community Health, University of Milano, Milan, Italy
| | - Neil J McHugh
- Royal National Hospital for Rheumatic Diseases (at Royal United Hospitals), Bath, UK.,Department of Pharmacy and Pharmacology, University of Bath, Bath, UK
| | - Sindhu R Johnson
- Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
| | - Marie Hudson
- Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Canada
| | - Francesco Boin
- UCSF Scleroderma Center, University of California San Francisco, San Francisco, CA
| | - Voon H Ong
- University College London Medical School, Royal Free Hospital, London, UK
| | | | | | - Marina Scolnik
- Rheumatology Section, Hospital Italiano de Buenos Aires, Argentina
| | - Mandana Nikpour
- The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia
| | | | | | - Dinesh Khanna
- University of Michigan Scleroderma Program, Ann Arbor, MI
| | - Ariane L Herrick
- Centre for Musculoskeletal Research, The University of Manchester, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester.,NIHR Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, UK
| |
Collapse
|
39
|
Pauling JD, Saketkoo LA, Domsic RT. Patient Perceptions of the Raynaud's Condition Score Diary Provide Insight Into Its Performance in Clinical Trials of Raynaud's Phenomenon: Comment on the Article by Denton et al. Arthritis Rheumatol 2018. [PMID: 29513932 DOI: 10.1002/art.40481] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- John D Pauling
- Royal National Hospital for Rheumatic Diseases at Royal United Hospitals and University of Bath, Bath, UK
| | - Lesley A Saketkoo
- Tulane University School of Medicine, Scleroderma and Sarcoidosis Patient Care and Research Center and University Medical Center Comprehensive, Pulmonary Hypertension Center, New Orleans, LA
| | | |
Collapse
|
40
|
Sand JMB, Lamy P, Juhl P, Siebuhr AS, Iversen LV, Nawrocki A, Larsen MR, Domsic RT, Franchimont N, Chavez J, Karsdal MA, Leeming DJ. Development of a Neo-Epitope Specific Assay for Serological Assessment of Type VII Collagen Turnover and Its Relevance in Fibroproliferative Disorders. Assay Drug Dev Technol 2018; 16:123-131. [PMID: 29493258 DOI: 10.1089/adt.2017.820] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Type VII collagen is the main component of the anchoring fibrils connecting the basement membrane to the underlying interstitial matrix. Mutations in the type VII collagen gene cause dystrophic epidermolysis bullosa. Increased levels of type VII collagen in the skin have been reported in patients with systemic sclerosis (SSc), whereas reduced levels in the airways have been related to asthma. This indicates that type VII collagen plays an important part in upholding tissue integrity and that its remodeling may lead to pathological states. The aim of this study was to investigate the role of type VII collagen remodeling in fibroproliferative disorders. We produced monoclonal antibody targeting a specific fragment of type VII collagen (C7M) released to the systemic circulation and developed a neo-epitope specific competitive enzyme-linked immunosorbent assay (ELISA). Biological relevance was evaluated in serum from patients with SSc or chronic obstructive pulmonary disease (COPD). The C7M ELISA was technically robust and specific for the C7M neo-epitope. Serum C7M levels were significantly elevated in two cohorts of patients with SSc and in patients with COPD as compared with healthy individuals (P < 0.0001). The C7M ELISA enabled quantification of type VII collagen turnover in serum. Elevated serum C7M levels indicated that the turnover rate of type VII collagen was significantly increased in patients with SSc or COPD, suggesting a pathological role. Thus, the C7M ELISA may become useful in future investigations of type VII collagen turnover in fibroproliferative disorders, and it may prove a valuable tool for evaluating novel anti-fibrotic drugs.
Collapse
Affiliation(s)
- Jannie M B Sand
- 1 Biomarkers and Research , Nordic Bioscience, Herlev, Denmark
| | - Patricia Lamy
- 1 Biomarkers and Research , Nordic Bioscience, Herlev, Denmark
| | - Pernille Juhl
- 1 Biomarkers and Research , Nordic Bioscience, Herlev, Denmark
| | | | - Line V Iversen
- 2 Department of Dermatology, Bispebjerg Hospital, University of Copenhagen , Copenhagen, Denmark
| | - Arkadiusz Nawrocki
- 3 Department of Biochemistry and Molecular Biology, University of Southern Denmark , Odense M, Denmark
| | - Martin R Larsen
- 3 Department of Biochemistry and Molecular Biology, University of Southern Denmark , Odense M, Denmark
| | - Robyn T Domsic
- 4 Department of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania
| | | | - Juan Chavez
- 5 Research and Early Development , Biogen, Cambridge, Massachusetts
| | | | - Diana J Leeming
- 1 Biomarkers and Research , Nordic Bioscience, Herlev, Denmark
| |
Collapse
|
41
|
Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med 2018; 378:35-47. [PMID: 29298160 PMCID: PMC5846574 DOI: 10.1056/nejmoa1703327] [Citation(s) in RCA: 336] [Impact Index Per Article: 56.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma) often has a devastating outcome. We compared myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation with immunosuppression by means of 12 monthly infusions of cyclophosphamide in patients with scleroderma. METHODS We randomly assigned adults (18 to 69 years of age) with severe scleroderma to undergo myeloablative autologous stem-cell transplantation (36 participants) or to receive cyclophosphamide (39 participants). The primary end point was a global rank composite score comparing participants with each other on the basis of a hierarchy of disease features assessed at 54 months: death, event-free survival (survival without respiratory, renal, or cardiac failure), forced vital capacity, the score on the Disability Index of the Health Assessment Questionnaire, and the modified Rodnan skin score. RESULTS In the intention-to-treat population, global rank composite scores at 54 months showed the superiority of transplantation (67% of 1404 pairwise comparisons favored transplantation and 33% favored cyclophosphamide, P=0.01). In the per-protocol population (participants who received a transplant or completed ≥9 doses of cyclophosphamide), the rate of event-free survival at 54 months was 79% in the transplantation group and 50% in the cyclophosphamide group (P=0.02). At 72 months, Kaplan-Meier estimates of event-free survival (74% vs. 47%) and overall survival (86% vs. 51%) also favored transplantation (P=0.03 and 0.02, respectively). A total of 9% of the participants in the transplantation group had initiated disease-modifying antirheumatic drugs (DMARDs) by 54 months, as compared with 44% of those in the cyclophosphamide group (P=0.001). Treatment-related mortality in the transplantation group was 3% at 54 months and 6% at 72 months, as compared with 0% in the cyclophosphamide group. CONCLUSIONS Myeloablative autologous hematopoietic stem-cell transplantation achieved long-term benefits in patients with scleroderma, including improved event-free and overall survival, at a cost of increased expected toxicity. Rates of treatment-related death and post-transplantation use of DMARDs were lower than those in previous reports of nonmyeloablative transplantation. (Funded by the National Institute of Allergy and Infectious Diseases and the National Institutes of Health; ClinicalTrials.gov number, NCT00114530 .).
Collapse
Affiliation(s)
- Keith M Sullivan
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Ellen A Goldmuntz
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Lynette Keyes-Elstein
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Peter A McSweeney
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Ashley Pinckney
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Beverly Welch
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Maureen D Mayes
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Richard A Nash
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Leslie J Crofford
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Barry Eggleston
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Sharon Castina
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Linda M Griffith
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Julia S Goldstein
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Dennis Wallace
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Oana Craciunescu
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Dinesh Khanna
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Rodney J Folz
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Jonathan Goldin
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - E William St Clair
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - James R Seibold
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Kristine Phillips
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Shin Mineishi
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Robert W Simms
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Karen Ballen
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Mark H Wener
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - George E Georges
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Shelly Heimfeld
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Chitra Hosing
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Stephen Forman
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Suzanne Kafaja
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Richard M Silver
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Leroy Griffing
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Jan Storek
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Sharon LeClercq
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Richard Brasington
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Mary E Csuka
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Christopher Bredeson
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Carolyn Keever-Taylor
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Robyn T Domsic
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - M Bashar Kahaleh
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Thomas Medsger
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| | - Daniel E Furst
- From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.)
| |
Collapse
|
42
|
Morgan ND, Shah AA, Mayes MD, Domsic RT, Medsger TA, Steen VD, Varga J, Carns M, Ramos PS, Silver RM, Schiopu E, Khanna D, Hsu V, Gordon JK, Gladue H, Saketkoo LA, Criswell LA, Derk CT, Trojanowski MA, Shanmugam VK, Chung L, Valenzuela A, Jan R, Goldberg A, Remmers EF, Kastner DL, Wigley FM, Gourh P, Boin F. Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database. Medicine (Baltimore) 2017; 96:e8980. [PMID: 29390428 PMCID: PMC5758130 DOI: 10.1097/md.0000000000008980] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Racial differences exist in the severity of systemic sclerosis (SSc). To enhance our knowledge about SSc in African Americans, we established a comprehensive clinical database from the largest multicenter cohort of African American SSc patients assembled to date (the Genome Research in African American Scleroderma Patients (GRASP) cohort).African American SSc patients were enrolled retrospectively and prospectively over a 30-year period (1987-2016), from 18 academic centers throughout the United States. The cross-sectional prevalence of sociodemographic, clinical, and serological features was evaluated. Factors associated with clinically significant manifestations of SSc were assessed using multivariate logistic regression analyses.The study population included a total of 1009 African American SSc patients, comprised of 84% women. In total, 945 (94%) patients met the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for SSc, with the remaining 64 (6%) meeting the 1980 ACR or CREST (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia) criteria. While 43% were actively employed, 33% required disability support. The majority (57%) had the more severe diffuse subtype and a young age at symptom onset (39.1 ± 13.7 years), in marked contrast to that reported in cohorts of predominantly European ancestry. Also, 1 in 10 patients had a severe Medsger cardiac score of 4. Pulmonary fibrosis evident on computed tomography (CT) chest was present in 43% of patients and was significantly associated with anti-topoisomerase I positivity. 38% of patients with CT evidence of pulmonary fibrosis had a severe restrictive ventilator defect, forced vital capacity (FVC) ≤50% predicted. A significant association was noted between longer disease duration and higher odds of pulmonary hypertension, telangiectasia, and calcinosis. The prevalence of potentially fatal scleroderma renal crisis was 7%, 3.5 times higher than the 2% prevalence reported in the European League Against Rheumatism Scleroderma Trials and Research (EUSTAR) cohort.Our study emphasizes the unique and severe disease burden of SSc in African Americans compared to those of European ancestry.
Collapse
Affiliation(s)
- Nadia D. Morgan
- Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
| | - Ami A. Shah
- Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
| | - Maureen D. Mayes
- Division of Rheumatology, University of Texas-McGovern Medical School, Houston, TX
| | | | | | - Virginia D. Steen
- Division of Rheumatology, Georgetown University School of Medicine, Washington, DC
| | - John Varga
- Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL
| | - Mary Carns
- Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL
| | - Paula S. Ramos
- Division of Rheumatology, Medical University of South Carolina, Charleston, SC
| | - Richard M. Silver
- Division of Rheumatology, Medical University of South Carolina, Charleston, SC
| | - Elena Schiopu
- Division of Rheumatology, University of Michigan, Ann Arbor, MI
| | - Dinesh Khanna
- Division of Rheumatology, University of Michigan, Ann Arbor, MI
| | - Vivien Hsu
- Division of Rheumatology, Robert Wood Johnson University, New Brunswick, NJ
| | - Jessica K. Gordon
- Division of Rheumatology, Hospital for Special Surgery, New York, NY
| | - Heather Gladue
- Department of Rheumatology, Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC
| | - Lesley A. Saketkoo
- Division of Rheumatology, Tulane University School of Medicine, New Orleans, LA
| | | | - Chris T. Derk
- Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
| | | | | | - Lorinda Chung
- Division of Rheumatology, Stanford University School of Medicine, Stanford, CA
| | - Antonia Valenzuela
- Division of Rheumatology, Stanford University School of Medicine, Stanford, CA
| | - Reem Jan
- Division of Rheumatology, University of Chicago Pritzker School of Medicine, Chicago, IL
| | - Avram Goldberg
- Division of Rheumatology, New York University Langone Medical Center, New York, NY
| | | | | | - Fredrick M. Wigley
- Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
| | - Pravitt Gourh
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA
| | - Francesco Boin
- Division of Rheumatology, University of California San Francisco, CA
| |
Collapse
|
43
|
Hsu VM, Denton CP, Domsic RT, Furst DE, Rischmueller M, Stanislav M, Steen VD, Distler JH, Korish S, Cooper A, Choi S, Schafer PH, Horan G, Hough DR. Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. J Rheumatol 2017; 45:405-410. [DOI: 10.3899/jrheum.161040] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/09/2017] [Indexed: 11/22/2022]
Abstract
Objective.To evaluate the safety and efficacy of pomalidomide (POM) on forced vital capacity (FVC), modified Rodnan skin score (mRSS), and gastrointestinal (GI) symptomatology over 52 weeks of treatment in patients with interstitial lung disease due to systemic sclerosis (SSc).Methods.Twenty-three adult patients diagnosed with SSc were randomized 1:1 POM:placebo (PBO).Results.Mean change at Week 52 from baseline in predicted FVC% −5.2 and −2.8; mRSS −2.7 and −3.7; and UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract (SCTC GIT 2.0) score 0.1 and 0.0, with POM and PBO, respectively. Statistical significance was not achieved for any of these 3 primary endpoints at 52 weeks.Conclusion.Because of recruitment challenges, subject enrollment was discontinued early. In an interim analysis, the study did not meet its Week 52 primary endpoints. Therefore, a decision was made to terminate all study phases. POM was generally well tolerated, with an adverse event profile consistent with the known safety and tolerability profile of POM in other diseases. Study results were neither positive nor negative because too few subjects were enrolled to make meaningful conclusions. Clinical Trials number: NCT01559129.
Collapse
|
44
|
Chung L, Fairchild RM, Furst DE, Li S, Alkassab F, Bolster MB, Csuka ME, Derk CT, Domsic RT, Fischer A, Frech TM, Gomberg-Maitland M, Gordon JK, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TAJ, Molitor JA, Preston IR, Schiopu E, Shapiro L, Hant F, Silver R, Simms R, Varga J, Steen VD, Zamanian RT. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clin Exp Rheumatol 2017; 35 Suppl 106:106-113. [PMID: 27908301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2016] [Accepted: 09/28/2016] [Indexed: 06/06/2023]
Abstract
OBJECTIVES To assess the utility of B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) in detecting and monitoring pulmonary hypertension (PH) in systemic sclerosis (SSc). METHODS PHAROS is a multicenter prospective cohort of SSc patients at high risk for developing pulmonary arterial hypertension (SSc-AR-PAH) or with a definitive diagnosis of SSc-PH. We evaluated 1) the sensitivity and specificity of BNP≥64 and NT-proBNP≥210 pg/mL for the detection of SSc-PAH and/ or SSc-PH in the SSc-AR-PAH population; 2) baseline and longitudinal BNP and NT-proBNP levels as predictors of progression to SSc-PAH and/or SSc-PH; 3) baseline BNP≥180, NT-proBNP≥553 pg/mL, and longitudinal changes in BNP and NT-proBNP as predictors of mortality in SSc-PH diagnosed patients. RESULTS 172 SSc-PH and 157 SSc-AR- PAH patients had natriuretic peptide levels available. Median BNP and NT-proBNP were significantly higher in the SSc-PH versus SSc-AR-PAH group. The sensitivity and specificity for SSc-PAH detection using baseline BNP≥64 pg/mL was 71% and 59%; and for NT-proBNP≥210 pg/mL, 73% and 78%. NT-proBNP showed stronger correlations with haemodynamic indicators of right ventricular dysfunction than BNP. Baseline creatinine, RVSP > 40 mmHg, and FVC%:DLco% ratio ≥1.8 were associated with progression from SSc-AR-PAH to SSc-PH but no association with individual or combined baseline BNP and NT-proBNP levels was observed. Baseline and follow-up BNP or NT-proBNP levels were not predictive of death, however, a composite BNP/NT-proBNP group predicted mortality (HR 3.81 (2.08-6.99), p<.0001). CONCLUSIONS NT-proBNP may be more useful than BNP in the detection and monitoring of PAH in SSc patients, but additional studies are necessary.
Collapse
Affiliation(s)
- Lorinda Chung
- Stanford University, Stanford, CA and VA Palo Alto Health Care System, Palo Alto, CA, USA.
| | | | | | | | - Firas Alkassab
- University of Massachusetts Medical School, Worcester, MA/University of North Carolina-Chapel Hill, Charlotte, NC, USA
| | | | | | - Chris T Derk
- University of Pennsylvania, Philadelphia, PA, USA
| | | | - Aryeh Fischer
- University of Colorado School of Medicine, Aurora, CO, USA
| | | | | | | | | | - Vivien Hsu
- Rutgers-RWJ Medical School, New Brunswick, NJ, USA
| | | | | | | | | | | | | | | | - Faye Hant
- Medical University of South Carolina, Charleston, SC, USA
| | - Richard Silver
- Medical University of South Carolina, Charleston, SC, USA
| | | | - John Varga
- Northwestern University, Chicago, IL, USA
| | | | - Roham T Zamanian
- Stanford University, Stanford, CA, and Vera Moulton Wall Center for Pulmonary Vascular Disease, USA
| |
Collapse
|
45
|
Pauling JD, Frech TM, Domsic RT, Hudson M. Patient participation in patient-reported outcome instrument development in systemic sclerosis. Clin Exp Rheumatol 2017; 35 Suppl 106:184-192. [PMID: 28516884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2016] [Accepted: 10/26/2016] [Indexed: 06/07/2023]
Abstract
OBJECTIVES The patient perspective captured using Patient-Reported Outcome (PRO) instruments provide insight into the patient condition not always captured by physician-derived assessment tools. Target patient population involvement is an essential component of PRO instrument development. We have reviewed the level of patient involvement in the development of PRO instruments used in the assessment of systemic sclerosis (SSc). METHODS A comprehensive literature review was undertaken to identify studies reporting PRO instruments in SSc. Studies were assessed to establish whether the PRO instruments had been developed specifically for SSc or adopted from other disease areas. Studies reporting PRO instruments specific for SSc were scrutinised for evidence of target patient population involvement in the development of the instrument. RESULTS A total of 58 PRO instruments that have been used in SSc research were identified. Twelve (21%) of these were developed specifically for outcome assessment within SSc populations. Of these, 5 (42%) had not reported any patient involvement in the development phase of the instrument. Five SSc PRO instruments (42%) involved target patient population in the domain/item generation stage. Four (33%) of SSc PRO instruments had undertaken cognitive interviewing to ensure item wording adequately captured the intended conceptual framework. CONCLUSIONS The majority of PRO instruments used to assess SSc have not involved significant target patient involvement in their development. By involving patients in the development of novel PRO instruments in SSc, we can ensure such instruments adequately capture the experiences most relevant to our patients.
Collapse
Affiliation(s)
- John D Pauling
- Royal National Hospital for Rheumatic Diseases, Bath; and Department of Pharmacy and Pharmacology, University of Bath, UK.
| | - Tracy M Frech
- University of Utah and Salt Lake Regional Veterans Affair Medical Center, Salt Lake City, UT, USA
| | - Robyn T Domsic
- University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - Marie Hudson
- Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Canada
| |
Collapse
|
46
|
Fuschiotti P, Larregina AT, Domsic RT, Stolz DB, Medsger TA, Lafyatis RA. Skin-resident effector memory CD8+CD28− T cells exhibit a pro-fibrotic phenotype in patients with systemic sclerosis. The Journal of Immunology 2017. [DOI: 10.4049/jimmunol.198.supp.210.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Loss of CD28 expression by CD8+ T cells occurs with age and during chronic inflammatory conditions. CD8+CD28− T cells are a heterogeneous cell subpopulation whose function ranges from immunosuppressive to effector. Here we analyzed the role of CD8+CD28− T cells in the pathogenesis of systemic sclerosis (SSc), a connective tissue disorder characterized by autoimmunity, vasculopathy and extensive cutaneous and visceral fibrosis. We show that the frequency of CD8+CD28− T cells is increased in the blood and affected skin of SSc patients, independent of patient age, and correlates with the extent of skin fibrosis. We found that the majority of skin-tropic CD8+CD28− T cells are resident in the skin lesions of patients in the early stage of the disease, exhibit an effector memory phenotype and present a strong cytolytic activity ex vivo. Skin-resident and circulating SSc CD8+CD28− T cells produce high levels of the pro-fibrotic cytokine IL-13, which induces collagen production by normal and SSc dermal fibroblasts. Thus, our findings indicate that CD8+CD28− T cells represent a pathogenic T-cell subset in SSc and likely play a critical role in the early stage of SSc skin disease.
Collapse
|
47
|
Gordon JK, Girish G, Berrocal VJ, Zhang M, Hatzis C, Assassi S, Bernstein EJ, Domsic RT, Hant FN, Hinchcliff M, Schiopu E, Steen VD, Frech TM, Khanna D. Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort. J Rheumatol 2017; 44:791-794. [PMID: 28298560 DOI: 10.3899/jrheum.160654] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/03/2017] [Indexed: 12/20/2022]
Abstract
OBJECTIVE To determine the inter/intraobserver reliability of the tender and swollen joint counts (TJC, SJC) and the modified Rodnan Skin Score (mRSS) in diffuse cutaneous systemic sclerosis (dcSSc) and to assess content validity of the TJC/SJC. METHODS Ten rheumatologists completed the SJC, TJC, and mRSS on 7 patients. Musculoskeletal ultrasound (MSUS) was performed. RESULTS Interobserver and intraobserver reliability for the TJC was 0.97 and 0.99, for the SJC was 0.24 and 0.71, and for the mRSS was 0.81 and 0.94, respectively. MSUS abnormalities did not correspond with SJC/TJC. CONCLUSION We demonstrate excellent inter- and intraobserver reliability for the mRSS and TJC in dcSSc. However, the SJC and TJC did not correspond to MSUS.
Collapse
Affiliation(s)
- Jessica K Gordon
- From the Department of Rheumatology, and Department of Epidemiology and Biostatistics, Hospital for Special Surgery; Department of Rheumatology, Columbia University, New York, New York; Department of Radiology, and Department of Biostatistics, University of Michigan; University of Michigan Scleroderma Program, Ann Arbor, Michigan; Department of Rheumatology, University of Texas, Houston, Texas; Department of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Rheumatology, Northwestern University, Chicago, Illinois; Department of Rheumatology, Georgetown University, Washington, DC; Department of Rheumatology, University of Utah, Salt Lake City, Utah, USA. .,J.K. Gordon, MD, MSc, Department of Rheumatology, Hospital for Special Surgery; G. Girish, MBBS, Department of Radiology, University of Michigan; V.J. Berrocal, MSc, PhD, Department of Biostatistics, University of Michigan; M. Zhang, PhD, Department of Epidemiology and Biostatistics, Hospital for Special Surgery; C. Hatzis, BA, Department of Rheumatology, Hospital for Special Surgery; S. Assassi, MD, MS, Department of Rheumatology, University of Texas; E.J. Bernstein, MD, MSc, Department of Rheumatology, Columbia University; R.T. Domsic, MD, MPH, Department of Rheumatology, University of Pittsburgh; F.N. Hant, DO, Department of Rheumatology, Medical University of South Carolina; M. Hinchcliff, MD, MS, Department of Rheumatology, Northwestern University; E. Schiopu, MD, University of Michigan Scleroderma Program; V.D. Steen, MD, Department of Rheumatology, Georgetown University; T.M. Frech, MD, MS, Department of Rheumatology, University of Utah; D. Khanna, MD, MS, University of Michigan Scleroderma Program.
| | - Gandikota Girish
- From the Department of Rheumatology, and Department of Epidemiology and Biostatistics, Hospital for Special Surgery; Department of Rheumatology, Columbia University, New York, New York; Department of Radiology, and Department of Biostatistics, University of Michigan; University of Michigan Scleroderma Program, Ann Arbor, Michigan; Department of Rheumatology, University of Texas, Houston, Texas; Department of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Rheumatology, Northwestern University, Chicago, Illinois; Department of Rheumatology, Georgetown University, Washington, DC; Department of Rheumatology, University of Utah, Salt Lake City, Utah, USA.,J.K. Gordon, MD, MSc, Department of Rheumatology, Hospital for Special Surgery; G. Girish, MBBS, Department of Radiology, University of Michigan; V.J. Berrocal, MSc, PhD, Department of Biostatistics, University of Michigan; M. Zhang, PhD, Department of Epidemiology and Biostatistics, Hospital for Special Surgery; C. Hatzis, BA, Department of Rheumatology, Hospital for Special Surgery; S. Assassi, MD, MS, Department of Rheumatology, University of Texas; E.J. Bernstein, MD, MSc, Department of Rheumatology, Columbia University; R.T. Domsic, MD, MPH, Department of Rheumatology, University of Pittsburgh; F.N. Hant, DO, Department of Rheumatology, Medical University of South Carolina; M. Hinchcliff, MD, MS, Department of Rheumatology, Northwestern University; E. Schiopu, MD, University of Michigan Scleroderma Program; V.D. Steen, MD, Department of Rheumatology, Georgetown University; T.M. Frech, MD, MS, Department of Rheumatology, University of Utah; D. Khanna, MD, MS, University of Michigan Scleroderma Program
| | - Veronica J Berrocal
- From the Department of Rheumatology, and Department of Epidemiology and Biostatistics, Hospital for Special Surgery; Department of Rheumatology, Columbia University, New York, New York; Department of Radiology, and Department of Biostatistics, University of Michigan; University of Michigan Scleroderma Program, Ann Arbor, Michigan; Department of Rheumatology, University of Texas, Houston, Texas; Department of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Rheumatology, Northwestern University, Chicago, Illinois; Department of Rheumatology, Georgetown University, Washington, DC; Department of Rheumatology, University of Utah, Salt Lake City, Utah, USA.,J.K. Gordon, MD, MSc, Department of Rheumatology, Hospital for Special Surgery; G. Girish, MBBS, Department of Radiology, University of Michigan; V.J. Berrocal, MSc, PhD, Department of Biostatistics, University of Michigan; M. Zhang, PhD, Department of Epidemiology and Biostatistics, Hospital for Special Surgery; C. Hatzis, BA, Department of Rheumatology, Hospital for Special Surgery; S. Assassi, MD, MS, Department of Rheumatology, University of Texas; E.J. Bernstein, MD, MSc, Department of Rheumatology, Columbia University; R.T. Domsic, MD, MPH, Department of Rheumatology, University of Pittsburgh; F.N. Hant, DO, Department of Rheumatology, Medical University of South Carolina; M. Hinchcliff, MD, MS, Department of Rheumatology, Northwestern University; E. Schiopu, MD, University of Michigan Scleroderma Program; V.D. Steen, MD, Department of Rheumatology, Georgetown University; T.M. Frech, MD, MS, Department of Rheumatology, University of Utah; D. Khanna, MD, MS, University of Michigan Scleroderma Program
| | - Meng Zhang
- From the Department of Rheumatology, and Department of Epidemiology and Biostatistics, Hospital for Special Surgery; Department of Rheumatology, Columbia University, New York, New York; Department of Radiology, and Department of Biostatistics, University of Michigan; University of Michigan Scleroderma Program, Ann Arbor, Michigan; Department of Rheumatology, University of Texas, Houston, Texas; Department of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Rheumatology, Northwestern University, Chicago, Illinois; Department of Rheumatology, Georgetown University, Washington, DC; Department of Rheumatology, University of Utah, Salt Lake City, Utah, USA.,J.K. Gordon, MD, MSc, Department of Rheumatology, Hospital for Special Surgery; G. Girish, MBBS, Department of Radiology, University of Michigan; V.J. Berrocal, MSc, PhD, Department of Biostatistics, University of Michigan; M. Zhang, PhD, Department of Epidemiology and Biostatistics, Hospital for Special Surgery; C. Hatzis, BA, Department of Rheumatology, Hospital for Special Surgery; S. Assassi, MD, MS, Department of Rheumatology, University of Texas; E.J. Bernstein, MD, MSc, Department of Rheumatology, Columbia University; R.T. Domsic, MD, MPH, Department of Rheumatology, University of Pittsburgh; F.N. Hant, DO, Department of Rheumatology, Medical University of South Carolina; M. Hinchcliff, MD, MS, Department of Rheumatology, Northwestern University; E. Schiopu, MD, University of Michigan Scleroderma Program; V.D. Steen, MD, Department of Rheumatology, Georgetown University; T.M. Frech, MD, MS, Department of Rheumatology, University of Utah; D. Khanna, MD, MS, University of Michigan Scleroderma Program
| | - Christopher Hatzis
- From the Department of Rheumatology, and Department of Epidemiology and Biostatistics, Hospital for Special Surgery; Department of Rheumatology, Columbia University, New York, New York; Department of Radiology, and Department of Biostatistics, University of Michigan; University of Michigan Scleroderma Program, Ann Arbor, Michigan; Department of Rheumatology, University of Texas, Houston, Texas; Department of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Rheumatology, Northwestern University, Chicago, Illinois; Department of Rheumatology, Georgetown University, Washington, DC; Department of Rheumatology, University of Utah, Salt Lake City, Utah, USA.,J.K. Gordon, MD, MSc, Department of Rheumatology, Hospital for Special Surgery; G. Girish, MBBS, Department of Radiology, University of Michigan; V.J. Berrocal, MSc, PhD, Department of Biostatistics, University of Michigan; M. Zhang, PhD, Department of Epidemiology and Biostatistics, Hospital for Special Surgery; C. Hatzis, BA, Department of Rheumatology, Hospital for Special Surgery; S. Assassi, MD, MS, Department of Rheumatology, University of Texas; E.J. Bernstein, MD, MSc, Department of Rheumatology, Columbia University; R.T. Domsic, MD, MPH, Department of Rheumatology, University of Pittsburgh; F.N. Hant, DO, Department of Rheumatology, Medical University of South Carolina; M. Hinchcliff, MD, MS, Department of Rheumatology, Northwestern University; E. Schiopu, MD, University of Michigan Scleroderma Program; V.D. Steen, MD, Department of Rheumatology, Georgetown University; T.M. Frech, MD, MS, Department of Rheumatology, University of Utah; D. Khanna, MD, MS, University of Michigan Scleroderma Program
| | - Shervin Assassi
- From the Department of Rheumatology, and Department of Epidemiology and Biostatistics, Hospital for Special Surgery; Department of Rheumatology, Columbia University, New York, New York; Department of Radiology, and Department of Biostatistics, University of Michigan; University of Michigan Scleroderma Program, Ann Arbor, Michigan; Department of Rheumatology, University of Texas, Houston, Texas; Department of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Rheumatology, Northwestern University, Chicago, Illinois; Department of Rheumatology, Georgetown University, Washington, DC; Department of Rheumatology, University of Utah, Salt Lake City, Utah, USA.,J.K. Gordon, MD, MSc, Department of Rheumatology, Hospital for Special Surgery; G. Girish, MBBS, Department of Radiology, University of Michigan; V.J. Berrocal, MSc, PhD, Department of Biostatistics, University of Michigan; M. Zhang, PhD, Department of Epidemiology and Biostatistics, Hospital for Special Surgery; C. Hatzis, BA, Department of Rheumatology, Hospital for Special Surgery; S. Assassi, MD, MS, Department of Rheumatology, University of Texas; E.J. Bernstein, MD, MSc, Department of Rheumatology, Columbia University; R.T. Domsic, MD, MPH, Department of Rheumatology, University of Pittsburgh; F.N. Hant, DO, Department of Rheumatology, Medical University of South Carolina; M. Hinchcliff, MD, MS, Department of Rheumatology, Northwestern University; E. Schiopu, MD, University of Michigan Scleroderma Program; V.D. Steen, MD, Department of Rheumatology, Georgetown University; T.M. Frech, MD, MS, Department of Rheumatology, University of Utah; D. Khanna, MD, MS, University of Michigan Scleroderma Program
| | - Elana J Bernstein
- From the Department of Rheumatology, and Department of Epidemiology and Biostatistics, Hospital for Special Surgery; Department of Rheumatology, Columbia University, New York, New York; Department of Radiology, and Department of Biostatistics, University of Michigan; University of Michigan Scleroderma Program, Ann Arbor, Michigan; Department of Rheumatology, University of Texas, Houston, Texas; Department of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Rheumatology, Northwestern University, Chicago, Illinois; Department of Rheumatology, Georgetown University, Washington, DC; Department of Rheumatology, University of Utah, Salt Lake City, Utah, USA.,J.K. Gordon, MD, MSc, Department of Rheumatology, Hospital for Special Surgery; G. Girish, MBBS, Department of Radiology, University of Michigan; V.J. Berrocal, MSc, PhD, Department of Biostatistics, University of Michigan; M. Zhang, PhD, Department of Epidemiology and Biostatistics, Hospital for Special Surgery; C. Hatzis, BA, Department of Rheumatology, Hospital for Special Surgery; S. Assassi, MD, MS, Department of Rheumatology, University of Texas; E.J. Bernstein, MD, MSc, Department of Rheumatology, Columbia University; R.T. Domsic, MD, MPH, Department of Rheumatology, University of Pittsburgh; F.N. Hant, DO, Department of Rheumatology, Medical University of South Carolina; M. Hinchcliff, MD, MS, Department of Rheumatology, Northwestern University; E. Schiopu, MD, University of Michigan Scleroderma Program; V.D. Steen, MD, Department of Rheumatology, Georgetown University; T.M. Frech, MD, MS, Department of Rheumatology, University of Utah; D. Khanna, MD, MS, University of Michigan Scleroderma Program
| | - Robyn T Domsic
- From the Department of Rheumatology, and Department of Epidemiology and Biostatistics, Hospital for Special Surgery; Department of Rheumatology, Columbia University, New York, New York; Department of Radiology, and Department of Biostatistics, University of Michigan; University of Michigan Scleroderma Program, Ann Arbor, Michigan; Department of Rheumatology, University of Texas, Houston, Texas; Department of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Rheumatology, Northwestern University, Chicago, Illinois; Department of Rheumatology, Georgetown University, Washington, DC; Department of Rheumatology, University of Utah, Salt Lake City, Utah, USA.,J.K. Gordon, MD, MSc, Department of Rheumatology, Hospital for Special Surgery; G. Girish, MBBS, Department of Radiology, University of Michigan; V.J. Berrocal, MSc, PhD, Department of Biostatistics, University of Michigan; M. Zhang, PhD, Department of Epidemiology and Biostatistics, Hospital for Special Surgery; C. Hatzis, BA, Department of Rheumatology, Hospital for Special Surgery; S. Assassi, MD, MS, Department of Rheumatology, University of Texas; E.J. Bernstein, MD, MSc, Department of Rheumatology, Columbia University; R.T. Domsic, MD, MPH, Department of Rheumatology, University of Pittsburgh; F.N. Hant, DO, Department of Rheumatology, Medical University of South Carolina; M. Hinchcliff, MD, MS, Department of Rheumatology, Northwestern University; E. Schiopu, MD, University of Michigan Scleroderma Program; V.D. Steen, MD, Department of Rheumatology, Georgetown University; T.M. Frech, MD, MS, Department of Rheumatology, University of Utah; D. Khanna, MD, MS, University of Michigan Scleroderma Program
| | - Faye N Hant
- From the Department of Rheumatology, and Department of Epidemiology and Biostatistics, Hospital for Special Surgery; Department of Rheumatology, Columbia University, New York, New York; Department of Radiology, and Department of Biostatistics, University of Michigan; University of Michigan Scleroderma Program, Ann Arbor, Michigan; Department of Rheumatology, University of Texas, Houston, Texas; Department of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Rheumatology, Northwestern University, Chicago, Illinois; Department of Rheumatology, Georgetown University, Washington, DC; Department of Rheumatology, University of Utah, Salt Lake City, Utah, USA.,J.K. Gordon, MD, MSc, Department of Rheumatology, Hospital for Special Surgery; G. Girish, MBBS, Department of Radiology, University of Michigan; V.J. Berrocal, MSc, PhD, Department of Biostatistics, University of Michigan; M. Zhang, PhD, Department of Epidemiology and Biostatistics, Hospital for Special Surgery; C. Hatzis, BA, Department of Rheumatology, Hospital for Special Surgery; S. Assassi, MD, MS, Department of Rheumatology, University of Texas; E.J. Bernstein, MD, MSc, Department of Rheumatology, Columbia University; R.T. Domsic, MD, MPH, Department of Rheumatology, University of Pittsburgh; F.N. Hant, DO, Department of Rheumatology, Medical University of South Carolina; M. Hinchcliff, MD, MS, Department of Rheumatology, Northwestern University; E. Schiopu, MD, University of Michigan Scleroderma Program; V.D. Steen, MD, Department of Rheumatology, Georgetown University; T.M. Frech, MD, MS, Department of Rheumatology, University of Utah; D. Khanna, MD, MS, University of Michigan Scleroderma Program
| | - Monique Hinchcliff
- From the Department of Rheumatology, and Department of Epidemiology and Biostatistics, Hospital for Special Surgery; Department of Rheumatology, Columbia University, New York, New York; Department of Radiology, and Department of Biostatistics, University of Michigan; University of Michigan Scleroderma Program, Ann Arbor, Michigan; Department of Rheumatology, University of Texas, Houston, Texas; Department of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Rheumatology, Northwestern University, Chicago, Illinois; Department of Rheumatology, Georgetown University, Washington, DC; Department of Rheumatology, University of Utah, Salt Lake City, Utah, USA.,J.K. Gordon, MD, MSc, Department of Rheumatology, Hospital for Special Surgery; G. Girish, MBBS, Department of Radiology, University of Michigan; V.J. Berrocal, MSc, PhD, Department of Biostatistics, University of Michigan; M. Zhang, PhD, Department of Epidemiology and Biostatistics, Hospital for Special Surgery; C. Hatzis, BA, Department of Rheumatology, Hospital for Special Surgery; S. Assassi, MD, MS, Department of Rheumatology, University of Texas; E.J. Bernstein, MD, MSc, Department of Rheumatology, Columbia University; R.T. Domsic, MD, MPH, Department of Rheumatology, University of Pittsburgh; F.N. Hant, DO, Department of Rheumatology, Medical University of South Carolina; M. Hinchcliff, MD, MS, Department of Rheumatology, Northwestern University; E. Schiopu, MD, University of Michigan Scleroderma Program; V.D. Steen, MD, Department of Rheumatology, Georgetown University; T.M. Frech, MD, MS, Department of Rheumatology, University of Utah; D. Khanna, MD, MS, University of Michigan Scleroderma Program
| | - Elena Schiopu
- From the Department of Rheumatology, and Department of Epidemiology and Biostatistics, Hospital for Special Surgery; Department of Rheumatology, Columbia University, New York, New York; Department of Radiology, and Department of Biostatistics, University of Michigan; University of Michigan Scleroderma Program, Ann Arbor, Michigan; Department of Rheumatology, University of Texas, Houston, Texas; Department of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Rheumatology, Northwestern University, Chicago, Illinois; Department of Rheumatology, Georgetown University, Washington, DC; Department of Rheumatology, University of Utah, Salt Lake City, Utah, USA.,J.K. Gordon, MD, MSc, Department of Rheumatology, Hospital for Special Surgery; G. Girish, MBBS, Department of Radiology, University of Michigan; V.J. Berrocal, MSc, PhD, Department of Biostatistics, University of Michigan; M. Zhang, PhD, Department of Epidemiology and Biostatistics, Hospital for Special Surgery; C. Hatzis, BA, Department of Rheumatology, Hospital for Special Surgery; S. Assassi, MD, MS, Department of Rheumatology, University of Texas; E.J. Bernstein, MD, MSc, Department of Rheumatology, Columbia University; R.T. Domsic, MD, MPH, Department of Rheumatology, University of Pittsburgh; F.N. Hant, DO, Department of Rheumatology, Medical University of South Carolina; M. Hinchcliff, MD, MS, Department of Rheumatology, Northwestern University; E. Schiopu, MD, University of Michigan Scleroderma Program; V.D. Steen, MD, Department of Rheumatology, Georgetown University; T.M. Frech, MD, MS, Department of Rheumatology, University of Utah; D. Khanna, MD, MS, University of Michigan Scleroderma Program
| | - Virginia D Steen
- From the Department of Rheumatology, and Department of Epidemiology and Biostatistics, Hospital for Special Surgery; Department of Rheumatology, Columbia University, New York, New York; Department of Radiology, and Department of Biostatistics, University of Michigan; University of Michigan Scleroderma Program, Ann Arbor, Michigan; Department of Rheumatology, University of Texas, Houston, Texas; Department of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Rheumatology, Northwestern University, Chicago, Illinois; Department of Rheumatology, Georgetown University, Washington, DC; Department of Rheumatology, University of Utah, Salt Lake City, Utah, USA.,J.K. Gordon, MD, MSc, Department of Rheumatology, Hospital for Special Surgery; G. Girish, MBBS, Department of Radiology, University of Michigan; V.J. Berrocal, MSc, PhD, Department of Biostatistics, University of Michigan; M. Zhang, PhD, Department of Epidemiology and Biostatistics, Hospital for Special Surgery; C. Hatzis, BA, Department of Rheumatology, Hospital for Special Surgery; S. Assassi, MD, MS, Department of Rheumatology, University of Texas; E.J. Bernstein, MD, MSc, Department of Rheumatology, Columbia University; R.T. Domsic, MD, MPH, Department of Rheumatology, University of Pittsburgh; F.N. Hant, DO, Department of Rheumatology, Medical University of South Carolina; M. Hinchcliff, MD, MS, Department of Rheumatology, Northwestern University; E. Schiopu, MD, University of Michigan Scleroderma Program; V.D. Steen, MD, Department of Rheumatology, Georgetown University; T.M. Frech, MD, MS, Department of Rheumatology, University of Utah; D. Khanna, MD, MS, University of Michigan Scleroderma Program
| | - Tracy M Frech
- From the Department of Rheumatology, and Department of Epidemiology and Biostatistics, Hospital for Special Surgery; Department of Rheumatology, Columbia University, New York, New York; Department of Radiology, and Department of Biostatistics, University of Michigan; University of Michigan Scleroderma Program, Ann Arbor, Michigan; Department of Rheumatology, University of Texas, Houston, Texas; Department of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Rheumatology, Northwestern University, Chicago, Illinois; Department of Rheumatology, Georgetown University, Washington, DC; Department of Rheumatology, University of Utah, Salt Lake City, Utah, USA.,J.K. Gordon, MD, MSc, Department of Rheumatology, Hospital for Special Surgery; G. Girish, MBBS, Department of Radiology, University of Michigan; V.J. Berrocal, MSc, PhD, Department of Biostatistics, University of Michigan; M. Zhang, PhD, Department of Epidemiology and Biostatistics, Hospital for Special Surgery; C. Hatzis, BA, Department of Rheumatology, Hospital for Special Surgery; S. Assassi, MD, MS, Department of Rheumatology, University of Texas; E.J. Bernstein, MD, MSc, Department of Rheumatology, Columbia University; R.T. Domsic, MD, MPH, Department of Rheumatology, University of Pittsburgh; F.N. Hant, DO, Department of Rheumatology, Medical University of South Carolina; M. Hinchcliff, MD, MS, Department of Rheumatology, Northwestern University; E. Schiopu, MD, University of Michigan Scleroderma Program; V.D. Steen, MD, Department of Rheumatology, Georgetown University; T.M. Frech, MD, MS, Department of Rheumatology, University of Utah; D. Khanna, MD, MS, University of Michigan Scleroderma Program
| | - Dinesh Khanna
- From the Department of Rheumatology, and Department of Epidemiology and Biostatistics, Hospital for Special Surgery; Department of Rheumatology, Columbia University, New York, New York; Department of Radiology, and Department of Biostatistics, University of Michigan; University of Michigan Scleroderma Program, Ann Arbor, Michigan; Department of Rheumatology, University of Texas, Houston, Texas; Department of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Department of Rheumatology, Northwestern University, Chicago, Illinois; Department of Rheumatology, Georgetown University, Washington, DC; Department of Rheumatology, University of Utah, Salt Lake City, Utah, USA.,J.K. Gordon, MD, MSc, Department of Rheumatology, Hospital for Special Surgery; G. Girish, MBBS, Department of Radiology, University of Michigan; V.J. Berrocal, MSc, PhD, Department of Biostatistics, University of Michigan; M. Zhang, PhD, Department of Epidemiology and Biostatistics, Hospital for Special Surgery; C. Hatzis, BA, Department of Rheumatology, Hospital for Special Surgery; S. Assassi, MD, MS, Department of Rheumatology, University of Texas; E.J. Bernstein, MD, MSc, Department of Rheumatology, Columbia University; R.T. Domsic, MD, MPH, Department of Rheumatology, University of Pittsburgh; F.N. Hant, DO, Department of Rheumatology, Medical University of South Carolina; M. Hinchcliff, MD, MS, Department of Rheumatology, Northwestern University; E. Schiopu, MD, University of Michigan Scleroderma Program; V.D. Steen, MD, Department of Rheumatology, Georgetown University; T.M. Frech, MD, MS, Department of Rheumatology, University of Utah; D. Khanna, MD, MS, University of Michigan Scleroderma Program
| |
Collapse
|
48
|
Li G, Larregina AT, Domsic RT, Stolz DB, Medsger TA, Lafyatis R, Fuschiotti P. Skin-Resident Effector Memory CD8 +CD28 - T Cells Exhibit a Profibrotic Phenotype in Patients with Systemic Sclerosis. J Invest Dermatol 2016; 137:1042-1050. [PMID: 28012718 DOI: 10.1016/j.jid.2016.11.037] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2016] [Revised: 11/20/2016] [Accepted: 11/28/2016] [Indexed: 11/16/2022]
Abstract
Loss of CD28 expression by CD8+ T cells occurs with age and during chronic inflammatory conditions. CD8+CD28- T cells are a heterogeneous cell subpopulation whose function ranges from immunosuppressive to effector. Here we analyzed the role of CD8+CD28- T cells in the pathogenesis of systemic sclerosis (SSc), a connective tissue disorder characterized by autoimmunity, vasculopathy, and extensive cutaneous and visceral fibrosis. We show that the frequency of CD8+CD28- T cells is increased in the blood and affected skin of SSc patients, independent of patient age, and correlates with the extent of skin fibrosis. We found that most skin-tropic CD8+CD28- T cells are resident in the skin lesions of patients in the early stage of the disease, exhibit an effector memory phenotype, and present a strong cytolytic activity ex vivo. Skin-resident and circulating SSc CD8+CD28- T cells produce high levels of the profibrotic cytokine IL-13, which induces collagen production by normal and SSc dermal fibroblasts. Thus, our findings indicate that CD8+CD28- T cells represent a pathogenic T-cell subset in SSc and likely play a critical role in the early stage of SSc skin disease.
Collapse
Affiliation(s)
- Gang Li
- Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Adriana T Larregina
- Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; McGowan Institute for Regenerative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Robyn T Domsic
- Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Donna B Stolz
- Department of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Thomas A Medsger
- Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Robert Lafyatis
- Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Patrizia Fuschiotti
- Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
| |
Collapse
|
49
|
Domsic RT, Lucas M, Nihtyanova SI, Denton CP, Wisniewski SR, Fine MJ, Kwoh CK, Medsger TA. Reply. Arthritis Rheumatol 2016; 69:242. [PMID: 27589673 DOI: 10.1002/art.39853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2016] [Accepted: 08/23/2016] [Indexed: 11/08/2022]
Affiliation(s)
- Robyn T Domsic
- University of Pittsburgh School of Medicine. Pittsburgh, PA
| | - Mary Lucas
- University of Pittsburgh School of Medicine. Pittsburgh, PA
| | | | | | | | - Michael J Fine
- Veterans Affairs Center for Health Equity, Research and Promotion, Veterans Affairs Pittsburgh Healthcare, Pittsburgh, PA
| | - C Kent Kwoh
- University of Arizona Arthritis Center, Tucson, AZ
| | | |
Collapse
|
50
|
Lammi MR, Mathai SC, Saketkoo LA, Domsic RT, Bojanowski C, Furst DE, Steen VD. Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension. Arthritis Rheumatol 2016; 68:740-8. [PMID: 26479414 DOI: 10.1002/art.39478] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Accepted: 10/15/2015] [Indexed: 02/07/2023]
Abstract
OBJECTIVE To compare time to clinical worsening (TTCW) based on initial oral therapy for pulmonary arterial hypertension (PAH) in patients with systemic sclerosis (SSc)-related PAH. METHODS Using data from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry (a multicenter prospective observational study enrolling SSc patients with incident pulmonary hypertension), we selected patients with group 1 PAH (World Health Organization Clinical Classification system) who received initial therapy (for 6 months) with an endothelin receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, or a combination of these 2 agents (ERA/PDE5 inhibitor). The main outcome was TTCW, defined as the first occurrence of death, PAH-related hospitalization, lung transplantation, initiation of parenteral prostacyclin treatment, or worsening symptoms. RESULTS Ninety-eight patients (24 in the ERA group, 59 in the PDE5 inhibitor group, and 15 in the ERA/PDE5 inhibitor group) were included. No significant differences in the baseline characteristics of the patients were observed. TTCW was significantly worse in patients in the ERA group compared with those in the PDE5 inhibitor group or the ERA/PDE5 inhibitor group. Ten patients (41.6%) in the ERA group died during the 3-year observation period, compared with 4 patients (6.8%) in the PDE5 inhibitor group and 1 patient (6.7%) in the ERA/PDE5 inhibitor group. Baseline factors that were independently associated with a shorter TTCW were initial treatment with an ERA (hazard ratio [HR] 2.63 [P = 0.009]), lower diffusing capacity for carbon monoxide (HR 0.69 per 10% of predicted change [P = 0.04]), and higher pulmonary vascular resistance (HR 1.10 per Wood unit change [P = 0.007]). CONCLUSION Compared with initial treatment with a PDE5 inhibitor or combination therapy with an ERA and a PDE5 inhibitor, initial therapy with an ERA in patients with SSc-related PAH was associated with significantly worse TTCW, even after adjustment for commonly accepted prognostic factors. Further study into the optimal initial oral therapy for patients with SSc-related PAH is needed.
Collapse
Affiliation(s)
- Matthew R Lammi
- Louisiana State University Health Sciences Center, New Orleans
| | | | | | | | | | | | | | | |
Collapse
|